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Abstract 
 
Melanocytes, Melanocytic Nevi, and Progression to Melanoma 
 
Andrew S. McNeal 
 
Benign melanocytic nevi form when melanocytes that acquire a BRAFV600E mutation 
undergo a period of rapid proliferation followed by subsequent growth-arrest.  Constitutive 
activation of MAPK signaling downstream of BRAF drives the initial proliferative phenotype. 
However, the factors that establish and maintain growth-arrest in nevi remain elusive.  
 Here we investigate the contributions of several potential mediators of BRAFV600E-induced 
growth arrest in nevus melanocytes. These mediators include the gene products of the CDKN2A-
CDKN2B genetic locus, nevus-enriched microRNAs MIR211-5p and MIR328-3p, as well as 
transcriptional networks associated with primary cilia expression. 
p16INK4A, the cyclin dependent kinase inhibitor encoded by CDKN2A, has historically been 
associated with nevus formation.  CDKN2B’s gene product, p15INK4B, remained under-studied in 
the context of nevus formation.  Using primary melanocytes isolated directly from human nevi and 
naturally expressing the BRAFV600E-acitvating mutation, nevi progressing to melanoma, and 
normal melanocytes engineered to inducibly express BRAFV600E, we showed that p15INK4B 
expression is required for growth arrest in nevi and that loss promotes progression to melanoma.  
Investigating the role of the p16INK4A tumor suppressor in nevus formation and progression to 
melanoma, we found that loss of p16INK4A contributes to melanocyte hypermotility in vitro and 
increases invasive and metastatic behavior of melanoma cell lines in vivo.  Using CRISPR-Cas9 
to engineer a cellular model of melanoma initiation from primary human melanocytes, we 
determined that E2F1 upregulation as a consequence of CDKN2A loss drives these new 
phenotypes. 
Additional acquired genetic alterations do not distinguish proliferating BRAFV600E 
melanocytes from their growth-arrested nevus counterparts, suggesting a role for regulatory 
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elements. We investigated the role of microRNAs in the initiation and maintenance of nevus 
growth arrest. Using primary human melanocytes, melanocytic nevi, and adjacent melanoma, we 
show that MIR211-5p and MIR328-3p are enriched in nevi compared to normal melanocytes, then 
subsequently downregulated in adjacent melanoma. Both MIR211-5p and MIR328-3p proved 
necessary effectors of BRAFV600E-induced growth arrest in human melanocytes. We identified 
microRNA target networks which, when suppressed, phenocopy BRAFV600E-induced growth arrest 
and converge on inhibition of AURKB to block cell cycle progression in primary human 
melanocytes. 
Similarly, expression of the primary cilium organelle has been shown to differentiate nevi 
from malignant melanoma.  Investigations of primary cilia-associated gene expression in matched 
nevus and melanoma cases demonstrates that transcriptional changes in core primary cilia genes 
and related signaling molecules accompanies loss of the organelle during progression to 
melanoma. 
Taken together, these data suggest that the BRAFV600E mutation leads to a cascade of 
intracellular changes that establish and maintain of growth arrest in human melanocytic nevi.   
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Chapter 1: Introduction  
 
 
Part 1. Overview of Melanocyte Biology 
 
Melanocytes are dendritic, pigment-producing cells.  Cytologically, they are characterized 
as having two or more dendritic processes that protrude from the main cell body (Fitzpatrick and 
Szabo, 1959).  Melanocytes are found in the uvea of the eye, the inner ear, the meninges of the 
brain, as well as in the bones and heart, however, they are most commonly associated with the 
skin (Yamaguchi and Hearing, 2014).  A defining feature of melanocytes is their ability to produce 
pigment, known as melanin, which contributes to the range of scale, feather, fur, and skin coloring 
that we observe in nature.  Melanin has two forms, a red/yellow pigment called pheomelanin and 
a brown/black pigment known as eumelanin.  In addition to their different coloration, eumelanin 
and pheomelanin also differ in their size, shape, and granule packaging (Lin and Fisher, 2007).  
Both types of melanin, however, are derived from the common precursor, tyrosine.  To begin 
melanogenesis (the process of making melanin), tyrosine is hydrolyzed to dopaquinone.  From 
here, the chemical synthesis pathways diverge for each type of melanin.  Due to the potential 
chemical risks posed by both melanin synthesis pathways, melanin production occurs in 
specialized lysosome-like structures called melanosomes.  Melanosomes are trafficked from 
melanocytes to adjacent keratinocytes where they provide protection against ultra violet radiation 
(UV) (Yamaguchi and Hearing, 2009). 
 The process of pigment production and trafficking from melanocytes to surrounding 
keratinocytes underlies the phenomenon known as “tanning”.  UV light from sun rays damage 
keratinocytes in the upper layers of the skin.  In response, keratinocytes secrete several 
molecules, the most well-studied of which is alpha melanocyte stimulating hormone or a-MSH.  
a-MSH binds to the melanocortin 1 receptor (MC1R), a G-protein coupled receptor (GPCR) 
expressed on the melanocyte cell membrane.  Upon stimulation by a-MSH, MC1R activates 
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adenyl cyclase, which in turn activates cyclic AMP (cAMP).  cAMP signaling activates Protein 
kinase A (PKA), which phosphorylates the transcription factor CREB.  CREB, in turn, binds the 
MITF promoter and induces melanin synthesis (Westerhof, 2006).  Although this is considered 
the primary pigmentation pathway, other peptides and hormones, such as estrogen, have been 
shown to stimulate pigment production in melanocytes (Natale et al., 2016).  Diversity in human 
pigmentation and tanning responses is thought to arise from mutations in the melanin signaling 
and synthesis pathways.  The balance of eumelanin and pheomelanin synthesis ultimately 
determines the pigmentation status of the individual.                      
 
Developmental lineage of melanocytes 
 
Neural Crest Precursors 
Melanocytes derive from neural crest cells which originate in the dorsal-most region of the 
neural tube.  The neural crest precursors of melanocytes migrate from the embryonic trunk and 
also give rise to cells of the nervous system including neurons and glia (Mort et al., 2015).  Models 
of chicken development demonstrated that the neural crest cells that become neurons and glia 
follow a ventral migration path through blocks of mesodermal cells that differentiate into the 
vertebral cartilage of the spine, while those that become melanocytes depart the trunk later and 
follow a path between the ectoderm and somites of the developing dermis (Erickson and Goins).  
In a seminal set of experiments, Henion and Weston isolated single migratory neural crest cells 
and allowed them to differentiate in vitro.  Some cells gave rise to a mixture of neurons, glia, and 
melanocytes.  Others gave rise to more restricted mixtures of neurons and glia or glia and 
melanocytes.  Still others differentiated solely into a single lineage (Henion and Weston, 1997).  
While this study definitively showed that melanocytes derived from neural crest progenitors, the 
range of differentiation outcomes suggested that other extracellular factors were at work to 
determine the neural crest progenitor’s ultimate cell fate.  
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Schwann Cell Precursors 
In addition to late-migrating neural crest cells of the trunk, Dupin et al. showed that 
Schwann cells, a type of glial cell of the peripheral nervous system, could be de-differentiated in 
vitro to a precursor of glia and melanocytes.  Today, there is a consensus that melanocytes 
originate from two distinct paths.  First, they can differentiate from neural crest cells following a 
dorsolateral migration.  Second, a Schwann cell glial/melanoblast progenitor migrating on the 
ventral path can also differentiate into melanocytes (Dupin et al., 2003). 
    
Transcriptional regulation of melanocyte identity 
 
Understanding of the developmental lineage of melanocytes is useful, but how are 
melanocytes defined at the molecular level?  Melanocyte inducing transcription factor (formerly 
microphthalmia- associated transcription factor) or MITF is widely accepted as the master-
regulator of melanocyte identity.  Mice lacking MITF (Steingrímsson et al., 2004) or fish missing 
the mitfa ortholog (Lister et al., 1999) cannot make melanocytes.  In 2003, Bejar et al. showed 
that expression of MITF in embryo-derived stem cells could induce melanocyte differentiation 
(Bejar, 2003).  As further evidence, humans with Waardenburg Syndrome or Tietz Syndrome 
have specific loss-of-function mutations in the MITF gene and are characterized by a lack of 
pigment (Cortés-González et al., 2016).   
 Although MITF is required for melanocyte differentiation, it is part of a larger transcriptional 
program that defines melanocyte identity.  In mammals, neural crest cells with active SRY-box 
transcription factor 10 (SOX10) expression become bi-potent progenitors of melanoblasts (a 
precursor of melanocytes) and glia.  Specific expression of SOX10 in conjunction with the paired 
box 3 (PAX3) gene has been shown to synergistically activate MITF (Potterf et al., 2000) 
(Watanabe et al., 2000).  MITF activation results in downstream activation of the dopachrome 
tautomerase (DCT) (also known as TRPM2) and KIT proto-oncogene receptor tyrosine kinase 
(KIT) genes, which promote further differentiation to the melanocyte.  Alternatively, MITF and KIT 
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can be inactivated in the melanoblast, while still retaining DCT expression, and these 
melanoblasts will form melanocyte stem cells (MSC) in the bulge of the hair follicle.  From the hair 
follicle bulge, MSCs can differentiate into rapidly- dividing transit-amplifying cells in which MITF 
and KIT are re-activated and in turn replenish the differentiated melanocytes of the hair follicle 
and surrounding epidermis (Yoshida et al. 1996).             
 To colonize the epidermis and developing hair follicle, melanoblasts must proliferate and 
migrate.  Failure to migrate can lead to un-pigmented patches seen in humans (Fleischman et al., 
1991), numerous mouse mutants (Bennett and Lamoreux, 2003), and in selectively bred pie- bald 
horses (Hauswirth et al., 2012).  Unexpectedly, in 2010, Li and colleagues demonstrated that 
crossing from the dermis to the epidermis is an active process that can occur without degradation 
of the basement membrane protein barrier (Li et al., 2010).  During mammalian development, 
melanoblasts are thought to cross the epidermal/dermal membrane, although a melanoblast 
population persists in the dermis.  Follicular melanocyte stem cells can act as an additional 
reservoir to replenish epidermal melanocytes (Nishimura, 2011).  A separate MSC pool, identified 
in sweat glands, can also give rise to epidermal melanocytes (Okamoto et al., 2014).  
Furthermore, under wound healing conditions induced by UV-radiation, or mechanical wounding, 
MSCs have the potential to leave the bulge niche of the hair follicle and supply sources of 
epidermal melanocytes (Chou et al., 2013).  Nevertheless, MSCs are a finite population and 
depletion of this population due to aging results in a failure to replenish follicular and epidermal 
melanocytes, leading to loss of hair pigmentation known as “greying” (Mort et al., 2015).        
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Part 2: Melanoma Biology 
 
 
Melanoma is a dangerous skin cancer 
Melanoma is a form of cancer arising from melanocytes.  Cutaneous melanoma 
(melanoma arising from melanocytes of the skin) is the predominant form of melanoma, however, 
rarer forms exist, named for the originating melanocyte population.  Non-cutaneous forms of 
melanoma include acral melanoma, which typically arises from melanocytes on the palms of 
hands or soles of feet as well as in the nail bed.  Uveal melanoma, arises from melanocytes of 
the uvea of the eyes (Chattopadhyay et al., 2016), and mucosal melanoma develops from 
melanocytes of the mucous membrane (Ablain et al., 2018).  Melanoma is the third most common 
form of skin cancer behind basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), 
however it accounts for the largest number of skin cancer deaths world-wide (Siegel et al., 2017).  
The prevalence and mortality rate of melanoma make it a pressing issue for researchers and 
physicians to understand the etiology of the disease and for which to develop new and improved 
therapies. 
Pathology of Melanoma 
Melanoma arises when a melanocyte acquires a series of DNA mutations that allow it to 
clonally expand.  Unchecked radial proliferation of melanocytes in the epidermis or at the 
basement membrane is referred to as melanoma in situ.  When proliferative melanocytes descend 
through the basement membrane into the dermis, or in some cases, descend further into the 
dermis, the disease is referred to as invasive melanoma.  Finally, malignant melanoma cells can 
acquire the ability to travel through the bloodstream and/or lymphatic system to colonize other 
organs, at which point the disease stage is referred to as metastatic melanoma. 
 According to The Cancer Genome Atlas (TCGA www.cancer.gov/about-
nci/organization/ccg/research/structural-genomics/tcga), which collected DNA and RNA 
sequencing from 333 primary or metastatic melanomas arising in 331 patients, there are four 
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main genetic sub-types of cutaneous melanoma (Akbani et al., 2015).  (Note: only 318 patients 
had matched tumor and germline tissue to determine the background mutation rate).  B-RAF 
proto-oncogene (BRAF), the most commonly mutated gene in the cohort, was mutated in 52% 
(166/318) of the melanoma tumors sequenced.  Among the BRAF mutations, the V600E 
(c.T1799A) mutation (124/166), which constitutively activates the kinase domain of the protein, 
occurred most frequently.  V600K (18/166) and V600R, which similarly activate the kinase domain 
(3/166) were also present in the cohort.  Activating mutations in the NRAS proto-oncogene 
(NRAS) were present in approximately 28% of the tumors and defined the second main sub-type.  
NRAS mutations were shown to be mutually exclusive of BRAF V600 mutations.  Neurofibromin 
1 (NF1) mutations defined the third main sub-type and accounted for approximately 14% of 
tumors.  NF1 mutations are thought to be loss of function mutations, which is consistent with its 
role as a GTP-ase activating protein known to suppress RAS activity.  Inactivation of NF1 could 
provide another means of activating RAS activity in the melanocyte.  Mutations in NF1 appear 
exclusive of tumors with BRAF V600 mutations, but can be found in tumors with activating NRAS 
mutations.  The final melanoma sub-type is known as “Triple Wildtype” and is simply characterized 
by a lack of hotspot mutations in BRAF, NRAS, or NF1.  KIT, GNAQ, GNA11, and EZH2 are 
genes often mutated in this cohort.   
 Nearly all of the melanomas in this study (94%) had mutations that activated the MAPK 
signaling pathway strongly suggesting that MAPK signaling, which drives cell proliferation, plays 
an essential role in melanomagenesis.  However, as I will discuss in the next section, MAPK 
activation alone is insufficient to drive melanocytes to malignant melanoma.  The TCGA study 
further revealed that MAPK activation was frequently paired with inactivating mutations in tumor 
suppressors, the most common of which was loss of the CDKN2A locus, which encodes p14ARF 
and p16INK4A proteins.  Additionally, mutations in the promoter of the telomerase (TERT) gene 
were common in melanoma (Akbani et al., 2015).   
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Working with paired samples of nevi (melanoma precursors) and adjacent melanoma, 
Shain and colleagues attempted to infer the order in which mutations are acquired in melanoma 
(Shain et al., 2015).  They found that melanocytes are most likely to acquire MAPKinase activating 
mutations first.  These mutations typically lead to a localized clonal expansion event known as a 
melanocytic nevus that I will discuss in the next section.  Without additional mutations, however, 
the mutant melanocytes will enter a durable growth-arrest phase.  Mutations in the TERT 
promoter, which constitutively activate TERT activity and enhance telomere maintenance, thus 
preventing replicative senescence, are thought to be acquired next and selected for upon 
transition to melanoma in situ.  Loss of tumor suppressor genes, such as p16INK4A, p15INK4B, 
p14ARF, are thought to be selected for during transition to invasive melanoma.  Shain and 
colleagues point out that no specific mutations have been shown to confer metastatic ability on 
melanocytes, however a host of additional mutations are found in invasive and metastatic 
melanomas that are not found in melanoma in situ.  These include, additional activating mutations 
to the MAPKinase pathway, such as loss of heterozygosity, or copy number gains, of the BRAF 
locus, activating mutations in pathways also implicated in cell proliferation such as PI3Kinase 
pathway activating mutations in AKT3 or loss of function mutations in AKT regulator PTEN, and 
mutation of SWI/SNF chromatin remodeling genes that lead to a shift towards the PRC2 complex.  
Additionally, later stage melanomas are characterized by increasing copy number variations 
(CNVs) and chromosomal instability (Shain et al., 2015). 
 
Animal Models of Melanomagenesis  
Mouse Melanoma Model 
One of the most widely used mouse models of melanoma is the tri-allelic BRafCA, PtenloxP, 
Tyr::CreERT2 model.  These mice harbor a constitutively active BRafV600E allele and deletes 
Pten in a 4-hyrdoxytamoxifen dependent manner. Cre-ERT2 is expressed under tyrosinase 
promoter (tyrosinase is a melanin enzyme expressed in late melanoblast development and 
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differentiated melanocytes).  BRAF mutation alone produced hyperpigmentation and benign 
melanocytic hyperplasia.  Depending on level and duration of transgene expression, dermal 
melanomagenesis with long latency can also occur (Goel et al., 2009).  If the BRAF transgenic 
mice are crossed with a mouse harboring genetic loss of p53 and/or CDKN2A, melanoma 
incidence greatly increases in the progeny.  Similarly, PTEN deletion causes rapid initiation of 
melanoma (100% penetrance in 4-5 weeks) with accompanying metastasis to lymph nodes and 
surrounding organs.  The introduction of degradation-resistant B-catenin further increased 
penetrance (Marsh Durban et al., 2013) (Pérez-Guijarro et al., 2017).  The engineering of the 
BRafCA, PtenloxP, Tyr::CreERT2 mouse model was an important step in understanding the etiology 
of melanoma.  It provides a genetic platform for interrogating the effects of potential oncogenes 
or tumor suppressors on the penetrance and progression of BRAFV600E-driven melanoma.  
However, this model has several caveats.  First, unlike humans, mice do not natively have inter-
follicular melanocytes in their epidermis, so the melanomas that arise in this model are from a 
follicular melanocyte pool.  This raises questions about whether the melanocytic cell of origin of 
the melanoma influences the trajectory of the melanoma transformation and whether this model 
recapitulates human melanoma progression.  Similarly, BRAFV600E expression alone in these 
mouse follicular melanocytes leads to melanoma transformation with low penetrance, which has 
not been observed in humans.  Likewise, BRAFV600E is expressed under a tyrosinase promoter, 
which is expressed in late melanoblast development and can therefore affect cells of the central 
nervous system in addition to melanocytes.   
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Zebrafish Melanoma Model  
The “miniCoopR” melanoma model in zebrafish was constructed by inserting an mitfa-
driven intronless MITF zebrafish minigene into a vector containing a mitfa promoter driving an 
EGFP transgene, or other gene of interest (Ceol et al., 2011).  The MITF minigene and transgene 
are flanked by Tol2 transposon arms then microinjected with the transposase into single cell 
zebrafish embryos, from (mitfa:BRAF(V600E));p53-/-;mitfa-/- zebrafish.  Because mitfa is 
essential for melanocyte differentiation, only cells that undergo successful incorporation of the 
mitfa minigene transposon will have viable melanocytes.  This system ensures that every 
melanocyte in the zebrafish will express mutant BRAF(V600E) on a p53 null background, in 
addition to any oncogene of interest cloned into the miniCoopR vector.  Ultimately, there is a 
mosaic rescue of neural crest cells, which will develop into patches of rescued melanocytes, some 
of which will develop melanoma (Heilmann et al., 2015).  The advantage of this system is that 
different transgenes can easily be swapped into the transposon vector to determine which 
oncogenes may contribute to melanoma formation.  However, a distinct disadvantage of the 
model is that BRAFV600E is driven by the mitfa promoter, indicating that not only melanocytes, 
but also cells of the nervous system will express the mutant oncogene.  Likewise, the mitfa 
promoter can be activated to varying degrees depending on the differentiation sate of the cell, 
which, depending on the cell or origin, may account for the mosaicism of BRAFV600E expression 
and the inconsistent penetrance of melanoma progression.  Furthermore, p53 is more often seen 
mutated to loss of function than fully deleted in melanomas and p53 mutations are typically seen 
in more advanced melanomas, so it is difficult to assess the role of this oncogene in the induction 
of melanoma in situ.     
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3D Reconstituted Human Skin Melanoma Model 
Arguably the most human of the current melanoma models adapted a model of 3-
dimensional organotypic human skin (Ridky et al., 2010), to culture primary human melanocytes 
in addition to primary human keratinocytes and primary human dermal fibroblasts.  Human skin 
was obtained from skin banks and incubated in PBS.  The epidermis was mechanically peeled, 
leaving a devitalized human dermis.  The dermis was then reconstituted with human fibroblasts 
for 7 days, at which point, it was elevated on a stand in a culture dish forming an air-liquid 
interface.  Primary human keratinocytes and melanocytes derived from human neonatal foreskin 
tissue were seeded onto the air interface of the dermis and allowed to reconstitute an epidermis 
over the following 4-5 days.  At this point, the cultures could be studied in vitro for up to 2 weeks, 
or grafted onto the back of immunocompromised mice and studied continuously for the lifespan 
of the mouse.  The ability to genetically manipulate the melanocytes in vitro before skin 
reconstitution allowed the researchers to directly characterize the effects of specific oncogenes 
on skin reconstitution and melanomagenesis in a human cellular context.  Another advantage is 
that the researcher is not limited by time and cost necessary to breed genetic mouse variants.  A 
disadvantage of this system is that melanomas do not form in a dish and only form when grafted 
onto an immunocompromised mouse, suggesting that murine factors contribute to the process of 
melanomagenesis in an uncontrolled manner.         
 
Current Therapies  
For patients with early stage melanoma, surgical excision is the most effective option and 
is often curative.  For patients with unresectable, metastatic, or otherwise late-stage disease, 
small molecule drug and immunotherapies provide two current options for treatment.  Drug 
treatment is based on the principle that MAPK pathway activation drives melanoma proliferation.  
In 2011 vemurafenib and dabrafenib, which specifically inhibit dimerization of mutant BRAFV600E 
and render it incapable of phosphorylating MEK, were approved by the FDA for use in BRAF 
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mutant melanomas.  Although RAF inhibition initially shrank melanomas, it was soon discovered 
that patients treated with BRAF inhibitors relapsed after several months of treatment as sub-
populations of tumor cells developed resistance (Sharma et al. 2012) (Sharma et al., 2012).  In 
an attempt to overcome this resistance, MEK inhibitors, such as cobimetinib and trametinib, were 
added to treatment.  The combination of these two inhibitors produced response rates of 
approximately 70% and progression-free survival of approximately 12 months (Leonardi et al., 
2018).    
 A second treatment modality emerged with the advent of immunotherapy.  Research into 
tumor- immune system interactions found that although lymphocytes are often present in the 
tumor microenvironment, these cells were unable to mount an immune challenge to the tumor 
cells (Grivennikov et al., 2010).  Studies of cytotoxic T Cells (CD8+ cells) uncovered the need for 
complex signaling to activate a T Cell response that was absent in most tumor microenvironments 
(Bouwhuis et al., 2010) (Francisco et al., 2009).  This research resulted in the development of 
immune checkpoint inhibiting antibodies such as anti-programmed cell death protein 1 (anti-PD1) 
and anti- cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA4) (Topalian et al., 2012) (Hodi 
et al., 2010).  Immune checkpoint inhibitor therapy has lower rates of response (~30%) in 
comparison to MAPKinase inhibitors, however, this treatment can confer more durable responses 
with some patients showing complete clearance of tumors and no recurrence several years post-
treatment (Franklin et al., 2017).   
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Part 3: Melanocytic Nevus Biology 
 
Melanocytic nevi, commonly known as “moles”, are comprised of clonal expansions of 
melanocytes and often present as pigmented lesions, or macules, on the surface of the skin 
(Bastian, 2014).  Many forms of melanocytic nevi exist, each possessing unique histology and 
molecular genetics.  Nevi are broadly divided into two categories: 1. Acquired nevi and 2. 
Congenital nevi.  Congenital nevi are thought to form in-utero during development.  These nevi 
typically grow larger than acquired nevi, in some cases covering 50% of an individual’s body (Roh 
et al., 2015).  Acquired nevi arise after birth due to the acquisition of mutations and/or copy 
number changes to chromosomal segments.  Acquired nevi can be further divided into three 
primary groups defined by the position of the constituent melanocytes in the skin.  Junctional nevi 
comprise melanocytes confined to the epidermis.  Intradermal nevi contain melanocytes in the 
dermis, and compound nevi have melanocytes spanning the epidermal and dermal compartments 
(Damsky and Bosenberg, 2017). 
Melanocytic Nevus Types 
An array of nevus types, each characterized by a unique histology, populate the junctional, 
intradermal, and compound nevus categories.  These include, but are not limited to: common 
nevus, Spitz nevus, Hori’s nevus, Becker’s nevus, and blue nevus.  Spitz nevi, named for the 
pioneering dermatopathologist Sophie Spitz (1910-1956), were once thought to be juvenile 
melanomas.  Further research demonstrated that these lesions are typically benign lesions of 
vertically arranged melanocyte nests with spindled and epithelioid morphology.  Spitz nevi are 
further characterized by multinucleate or mononucleate giant cells, large pigmented spindle cells, 
and pigmentation mainly in the superficial part of the lesion (Manchi and Canzonieri, 2019).  Hori’s 
nevus is a pigmentation disorder reported most often in middle-aged Asian women and presents 
as multiple brown-grey or blue-brown macules (Kaur et al., 2019).  Becker’s nevus, first reported 
by dermatologist Samuel W. Becker (1894-1964), typically affects males.  This nevus is 
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characterized by a large area of hyperpigmentation and excessive hair growth (Happle, 2017).  
Blue nevi are rare, tend to be nodular, and present with blue-grey hues on the epidermis 
(Borgenvik et al., 2017).  In contrast to the previously described nevus types, which occur at low 
frequency across the population, common nevi are the most prevalent form of melanocytic nevi 
and will be the subject of this work.   
Common melanocytic nevi 
Common melanocytic nevi generally appear as flat, uniformly pigmented, and symmetric 
spheres or ellipses in the epidermis with a radius of several millimeters (Damsky and Bosenberg, 
2017).  These nevi can arise at any time in a person’s life, however, the greatest number are 
acquired from childhood to ~30 years of age.  After 30 the rate of new common nevus acquisition 
typically decreases and nevus regression, a poorly understood process wherein nevi disappear 
from the skin, begins to occur (Stegmaier, 1959).  Viewed in cross-section under the microscope, 
common nevi have two distinct histological features - nesting and maturation.  Nesting describes 
the tendency of nevus melanocytes to form clusters of cells or “nests” within the tissue.  Maturation 
occurs in nevi with a dermal component and describes the gradual and progressive change in 
nest architecture and cell shape.  As nevi penetrate deeper into the dermis, nest size decreases 
along with the nuclear volume and pigment production of the constituent melanocytes (Damsky 
and Bosenberg, 2017).  The complex nature of melanocyte cytology within nevi suggests that 
both cell intrinsic and extrinsic factors, such as the microenvironment, converge to dictate the 
ultimate dimensions and morphology of the nevus.   
Mutations driving nevus formation 
Considerable research has been conducted in an attempt to define the molecular 
processes that give rise to melanocytic nevi.  DNA sequencing of nevi and surrounding normal 
tissue provided the first insights into genomic changes that underlie nevus formation.  In 2003, 
Pollock and colleagues published work showing that 63 of 77 nevi they sequenced (82%) had 
activating mutations in the BRAF proto-oncogene, with c.T1799A (p.V600E) as the dominant 
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mutation (Pollock et al., 2003).  Subsequent sequencing efforts confirmed Pollock’s finding and 
found that activating mutations in NRAS proto-oncogene are commonly found in congenital nevi.  
Spitz nevi often have HRAS proto-oncogene mutations as well as chromosomal copy number 
alterations (Bastian et al., 2000), and GNAQ/GNA11 mutations are common in blue nevi (Roh et 
al., 2015).  Importantly, BRAF, NRAS, HRAS, and GNAQ/GNA11 are all components of the MAPK 
signaling pathway, a central regulator of cellular proliferation (Dhillon et al., 2007) (Park et al., 
2018).  The prevalence of single, activating mutations in genes encoding key proteins of the 
MAPK signaling pathway suggests that melanocytic nevi arise from the rapid clonal expansion of 
a single mutant melanocyte. 
Two main hypotheses exist to explain how melanocytes acquire these activating MAPK 
pathway mutations.  The first implicates UV light from sun exposure, as many melanocytic nevi 
appear on sun exposed or sun damaged skin.  Although melanomas have high UV signature 
mutation burdens, there is no direct evidence that UV light is the causative agent for the most 
common BRAF, NRAS, or HRAS mutations.  Furthermore, the T>A transversion that results in 
the BRAF(V600E) mutation, the most common in melanocytic nevi, is not part of the canonical 
UV signature of C>T or CC>TT (cite).  Likewise, individuals with Xeroderma Pigmentosa, who 
have a deficiency nucleotide excision repair pathways necessary to repair UV-induced DNA 
damage, rarely develop melanomas with BRAF(V600E) mutations (Masaki et al., 2014).  The 
second hypothesis suggests that these mutations form as the product of oxidative stress, or as a 
combination of UV light and oxidative stress.  In this model, reactive oxygen species interfere with 
normal DNA replication leading to adducts in the DNA, which if not properly repaired, give rise to 
mutations (Venza et al., 2015). 
 
Why study BRAFV600E-driven nevi? 
While the specific mutagens remain unclear, the phenotype induced by activating 
mutations in the MAPK pathway is well described.  Rapid clonal expansion leads to nests of 
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melanocytes and subsequent growth arrest establishes the boundaries of the melanocytic nevus.  
For the remainder of this work, I will focus on common melanocytic nevi driven by the 
BRAF(V600E) mutation.  Unlike activating NRAS and HRAS mutations, which occasionally lead 
to nevi in human skin but more often lead directly to hyperproliferation and malignant disease, the 
activating V600E mutation of the BRAF proto-oncogene is thought to predominately induce nevus 
formation. 
Common nevi driven by BRAFV600E mutations are interesting for numerous reasons.  First, 
approximately 50% of melanomas are also driven by BRAFV600E and thought to arise when 
previously quiescent nevus cells re-enter the cell cycle and begin proliferating.  Therefore, 
understanding how nevi form and how they can transition to melanoma becomes crucial to 
discovering more efficacious treatments for the disease.  Second, because they are usually visible 
in the skin and because each defined stage of melanoma progression can be captured 
histologically, BRAFV600E nevi provide a unique window into the entire process of tumorigenesis 
from acquisition of an initiating mutation to metastasis.  Finally, since most BRAFV600E nevi remain 
innocuous for the entirety of an individual’s life, these lesions provide a fascinating opportunity to 
study the cell intrinsic and extrinsic factors that play a role in resisting oncogenic transformation. 
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Part 4: microRNA Biology 
Overview of microRNA function 
microRNAs are small non-coding RNAs approximately 20-22 nucleotides in length.  They 
are found in extragenic sequences of the genome (Bartel, 2004), as well as in the exons or introns 
of genes (Rodriguez, 2004) (Okamura et al., 2007).  microRNAs were first reported in a pair of 
1993 papers by Lee and colleagues and Wightman and colleagues in Caenorhabditis elegans (C. 
elegans), a species of roundworm.  These papers described lin-4 as a 21 nucleotide RNA that 
could partially base pair with sequences in the 3’ UTR of the mRNA of a gene called lin-14.  This 
partial base-pairing activity ultimately caused the inhibition of LIN-14 protein expression.  When 
measuring the effects of lin-4 on lin-14 mRNA, the authors found that LIN-14 mRNA expression 
was unaffected by lin-4 binding, and that lin-14 mRNA was still able to bind to the polyribosome 
(Lee et al., 1993) (Wightman et al., 1993).  These findings therefore suggested a model whereby 
microRNAs regulated mRNA translation. 
In 2000, two groups published work describing the activity of a second C. elegans 
microRNA named let-7, which post-transcriptionally inhibited lin-41 mRNA by binding a pair of 
sequences in the lin-41 3’ UTR (Pasquinelli et al., 2000) (Reinhart et al., 2000).  Besides 
confirming the mechanism of microRNA regulation proposed by Lee and Wightman, the discovery 
or let-7 precipitated the finding that this microRNA is conserved broadly among animal species, 
including in humans (Pasquinelli et al., 2000).  Further research into animal microRNAs 
demonstrated that microRNAs could also directly regulate mRNA levels.  Initially, experimental 
data showed that miRNA:target duplexes with imperfect base pairing resulted in inhibition of 
mRNA translation (Bartel, 2004).  If, however, significant perfect pairing occurs between the 
miRNA and target mRNA (including the seed sequence of the miRNA), the target mRNA itself 
can be cleaved and degraded (Park and Shin, 2014).  This mode of mRNA cleavage parallels 
that of small-interfering RNAs (si-RNAs), which had previously been described in plants (Elbashir 
et al., 2001).  Research in Drosophila and mammalian cell systems identified Arognaute 2 (AGO2) 
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as the protein responsible for mRNA cleavage (Hammond, 2001).  Finally, in 2005, Bagga et al. 
found that imperfect miRNA:mRNA base pairing of let-7  and lin-41 also led to the degradation of 
lin-41 target mRNA (Bagga et al., 2005).  This finding helped establish the current dogma that 
miRNAs can directly regulate mRNA transcript levels as well as regulate mRNA translation. 
microRNA processing 
 In mammalian cells, microRNAs are initially transcribed from their genomic positions in 
the nucleus by Polymerase II (POLII) as hairpins known as pri-miRNAs often in the range of 80-
100 nucleotides.  The hairpin then complexes with the micro-processing unit composed of DGCR8 
and DROSHA proteins.  This unit trims the longer hairpin down to a hairpin of shorter length 
known as the pre-miRNA.  The pre-miRNA is subsequently exported from the nucleus to the 
cytoplasm through a nuclear pore complex comprised of Exportin 5 (XPO5) and RanGTP.  Once 
in the cytoplasm, the pre-miRNA hairpin is further cleaved by a protein complex including DICER1 
and TRBP.  This cleavage produces two independent microRNAs with the designations 5’ or 3’, 
depending on their position in the pre-miRNA hairpin.  From here, the mature microRNA (now 
approximately 20-22 nucleotides) can be loaded into the binding pocket of Argonaute proteins 
(primarily AGO2 in mammalian cells) and bind complementary sequences in the 3’ UTRs of target 
mRNAs.  As previously described, miRNA:mRNA base pairing typically results in to both 
translational inhibition and mRNA degradation (Shukla et al., 2012).    
microRNAs regulate multiple genes 
 The large number of potential miRNA binding sites found in the 3’UTR of genes suggests 
that individual miRNAs have the potential to regulate numerous genes simultaneously.  Indeed, 
multiple groups have shown that overexpression of mature miRNA sequences (miRNA mimics) 
in cells induces changes in mRNA transcript levels across a wide range of genes (Guo et al., 
2010) (Thomson et al., 2013).  The advent of High Throughput Sequencing of RNA Isolated by 
Crosslinking Immunoprecipitation (HITS CLIP) enabled researchers to crosslink miRNA:mRNA 
complexes to AGO2 and the sequence mRNAs bound to immunoprecipitated AGO2 protein 
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(Darnell, 2010).  This method further confirmed the finding that miRNAs simultaneously regulated 
many mRNAs through direct binding to their 3’ UTRs and permitted the identification of miRNA 
specific mRNA targets at a fixed time point.  Similarly, large-scale proteomic analyses of cells 
post-miRNA overexpression or knockdown led to the complementary finding that miRNAs had 
profound effects on translation of target mRNAs (Baek et al., 2008).  The hunt for microRNA 
targets across the genome spawned the construction of several algorithms that follow defined 
sets of rules dictating which binding sites in the 3’ UTR of mRNAs would result in target mRNA 
regulation (Lewis et al., 2003) (Agarwal et al., 2015).  These computational methods of identifying 
potential miRNA targets resulted in the construction of target databases, most notably TargetScan 
(Lewis et al., 2005). 
 Despite the established rules for miRNA target prediction, the identification of functional 
miRNA targets remains highly context dependent.  mRNAs targeted by a miRNA in one cell type 
may not be transcribed in another cell type.  miRNA overexpression studies have shown that 
mRNA targets with a low score based on computational prediction may indeed be regulated when 
higher scoring targets are absent or in low abundance, or when the concentration of the miRNA 
exceeds a certain level.  Additional studies have shown that mRNAs with miRNA target 
sequences in their 5’ UTR (Lytle et al., 2007) or even the gene body may also be regulated by 
miRNA binding, however, the evidence supporting these claims remains controversial (Chi et al., 
2009).  These experimental findings argue strongly that potential transcript targets of the miRNA 
must be validated within the cell type of interest through measurements of mRNA and protein 
expression in response to miRNA manipulation.  Furthermore, these observations raise a series 
of questions regarding the importance of both miRNA and potential target mRNA concentrations, 
as well as the availability of Argonaute protein occupancy in the cell when determining specific 
miRNA targets. 
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Part 5: Role of miRNAs in melanoma 
Evolutionary history and experimental observation suggest that miRNAs contribute to cell 
differentiation and cell state maintenance by buffering against changes in target gene networks 
(Ebert and Sharp, 2012) (Berezikov, 2011) (Parchem et al., 2014).  Transitions from differentiated 
cells to tumor cells can be viewed as a subversion of miRNA buffering capacity resulting in 
reprogramming of a cell’s transcriptional networks (Schmiedel et al., 2015).  Work by Lu et al. 
provides further evidence for this by showing that total miRNA diversity decreases in tumors 
versus normal tissue, suggesting that loss of miRNA expression might lead to remodeling of the 
intracellular environment thereby lowering the barrier to tumorigenesis (Lu et al., 2005). 
 Consistent with these observations, small RNA sequencing of human melanoma tumors 
or melanoma cell lines have identified miRNAs differentially expressed in comparison to human 
melanocytes, including miR-17 (Nemlich et al., 2013), miR-221 (Kanemaru et al., 2011), miR-
146a (increased) (Forloni et al., 2014) and miR-211 (Levy et al., 2010), miR-125b (Wandler et al., 
2017) , miR-206 (decreased) (Georgantas et al., 2014).  Moreover Ren et al. show that miR 143, 
miR-34a, and miR-29a are upregulated in human melanocytes transduced with lentiviral 
BRAF(V600E), suggesting that these miRNAs are expressed in an effort to counter BRAF-
induced hyperproliferation (Ren et al., 2012).  Taken together, these findings support the 
hypothesis that microRNA expression is dysregulated during progression from normal 
melanocytes to malignancy.  Furthermore, these results argue that a thorough understanding of 
the dynamics of microRNA expression and target regulation from normal melanocytes to 
melanocytic nevi and melanoma may be essential to understanding the early events that lead to 
melanoma initiation and progression.  
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Chapter 2: BRAFV600E induces growth arrest in human melanocytes 
to form melanocytic nevi. 
 
 
 
Part 1: Theories of BRAFV600E-mediated growth arrest in melanocytes. 
 
To develop more efficacious melanoma therapies, scientists and physicians sought to 
determine how nevus cells restrain mutant BRAF-driven proliferative signaling and discover which 
elements are lost in progression to malignant disease.  Beginning in the early 2000s, researchers 
have inferred that the acquisition of the activating V600E mutation in the BRAF proto-oncogene 
is the founding genetic event that causes melanocytes to first proliferate and then undergo growth 
arrest.  Numerous theories have emerged to explain BRAFV600E-induced growth-arrest or 
“senescence”, as it is widely referred to in scientific literature, that forms the melanocytic nevus.  
Despite the plethora of explanations, nearly all converge on the principle that aberrant MAPK 
signaling downstream of BRAFV600E expression induces a cascade of intracellular changes that 
contribute to the establishment and/or maintenance of cell cycle arrest.  In this section, I will 
discuss several of these theories and their supporting evidence before detailing my own 
investigations into nevus formation.     
In 2006, Uribe and colleagues sought to understand why MAPK signaling downstream of 
BRAFV600E was repressed in nevi in comparison with primary melanomas if both lesions expressed 
the same mutation (Cohen et al., 2002) (Jørgensen and Holm, 2003).  By staining formalin fixed 
cutaneous tissue sections, they found that whereas melanoma samples had increased 
phosphorylation of extracellular signal regulating kinases 1/2 (ERK1/2), a downstream target of 
BRAFV600E activity, nevi had low levels of phospho-ERK1/2.  They posited that BRAFV600E 
expression must induce negative feed-back loops that ultimately dampen MAPK signaling.  This 
hypothesis was consistent with contemporaneous studies of MAPK signaling regulation in the 
presence or absence of BRAFV600E expression (Uribe et al., 2006).  Courtois-Cox et al. published 
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work suggesting that activation of RAS or RAF signaling induced negative feedback signals from 
RAS protein regulators including RasGAPs, RasGEFs, and SPROUTY proteins.  Relieving RAS 
protein inhibition by introducing shRNAs against NF1 (itself a RasGAP), the authors showed that 
in primary diploid human fibroblasts, RAS signaling was transiently activated followed by 
proliferation arrest.  They further identified a coordinated intracellular response wherein pro-
mitogenic phosphoinositide 3-kinase (PI3K) signaling was downregulated in response to RAS 
activation and anti-mitogenic forkhead box (FOXO) family of transcription factors was upregulated 
(Courtois-Cox et al., 2006).        
A second hypothesis suggested that DNA hyper-replication from oncogenic activation 
triggered DNA Damage Response (DDR) pathways.  Di Micco and colleagues expressed a 
constitutively activated HRAS protein, HRASG12V, which was thought to drive cell proliferation in 
specific cases of squamous cell carcinoma and melanomas, in human diploid fibroblasts via 
lentiviral transduction.  Rather than increasing cell proliferation, proliferation dramatically 
decreased.  They further found that expression of HRASG12V led to increases in the numbers of 
active DNA replicons and led to asymmetric replication fork progression, damaging DNA.  They 
also showed that HRAS activation increased expression of DDR pathway proteins including p53 
and checkpoint kinase 2 (CHEK2) and that inhibition of the DDR pathway led to bypassing of 
senescence (Di Micco et al., 2006).  Also working in HRAS mutant human fibroblasts, Aird and 
colleagues demonstrated that aberrant MAPKinase pathway activation depleted intracellular 
stores of deoxyribonucleotide triphosphates (dNTPs), which are required for DNA synthesis.  
They found that ribonucleotide reductase unit M2 (RRM2) was a rate-limiting protein in DNA 
synthesis, specifically in S-phase, and that its suppression downstream of activated RAS 
signaling decreased nucleotide metabolism (Aird et al., 2013).  
In parallel with gene expression changes and increased DNA damage, researchers 
identified differences in chromatin structure between nevi and malignant melanoma.  Electron 
microscopy of fixed ultrathin sections of human nevus and melanoma tissue revealed a 
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compaction of chromatin, known as heterochromatin, that makes DNA less accessible to 
transcription factors.  In malignant melanoma samples, however, the chromatin favored a more 
open structure known as euchromatin.  These observations of differences in the chromatin 
structure between nevi and melanoma suggested that chromatin remodeling in nevi can silence 
key transcriptional targets stymying proliferation (Stolz et al., 1991) (Narita et al., 2003) 
(Bandyopadhyay et al., 2007). 
One of the longest studied contributions to melanocytic nevus growth arrest is the 
relationship between BRAFV600E and the upregulation of a family of cell cycle inhibitors known as 
cyclin dependent kinase inhibitors.  The cyclin dependent kinase 2A (CDKN2A) gene encodes 
two tumor suppressor proteins, p16INK4A and p14ARF.  CDKN2A expression is typically observed 
in nevi but regularly mutated to loss-of-function or deleted in melanoma.  p16INK4A functions by 
inhibiting Cyclin D- CDK4/6 complex phosphorylation of retinoblastoma (Rb), an event required 
for passage through the G1 phase of the cell cycle (McConnell et al., 1999).  Meanwhile, p14ARF 
inhibits mouse double minute 2 (MDM2), which in turn degrades p53, increasing p53 expression 
and activating the DDR pathway (Lohrum et al., 2000).  Due to the upregulation of p16INK4A and 
p14ARF expression in human nevus sections, and their molecular functions, it was accepted that 
these proteins provided “an effective cellular brake against BRAFV600E-mediated oncogenic 
signaling”.   
Michaloglou and colleagues directly investigated the connection between BRAFV600E and 
p16INK4A expression in normal human diploid melanocytes (in this case foreskin-derived 
melanocytes) in vitro.  To simulate the BRAF(V600E) mutation, they transduced human 
melanocytes with a lentiviral vector harboring the BRAF(V600E) transgene.  They observed that 
BRAFV600E expression induces growth-arrest in melanocytes.  Likewise, BRAFV600E induced 
p16INK4A expression in a mosaic pattern in growth-arrested melanocytes, but p14ARF expression 
did not increase.  They then expressed BRAFV600E or p16INK4A in human diploid fibroblasts and 
showed that expression of either transgene significantly reduced proliferation over the course of 
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11 days.  Somewhat surprisingly, knockdown of p16INK4A via shRNA could not rescue 
BRAFV600E-induced arrest in fibroblasts, suggesting that it was sufficient but not necessary for 
growth-arrest induction (Figure 1).  Moreover, they argued that p16 regulation of RB rather than 
p14 induction of p53 contributed to growth arrest, as they failed to detect upregulation of p53 in 
nevus sections.   
Finally, their work challenged a longstanding hypothesis in the field of nevus growth arrest 
which asserted that nevus melanocytes ceased to proliferate due to a critical shortening of their 
telomeres.  Telomeres are repeating motifs of adenine and thymidine bases found at the termini 
of chromosomes and, in normal physiology, these repeats protect DNA integrity during replication.  
Hayflick et al. proposed that cells with critically shortened telomeres (those that had reached the 
“Hayflick Limit”) could not replicate their DNA, effectively inhibiting proliferation.  Through telomere 
staining in sections of human nevi, Michaloglou et al., however, found no apparent loss of 
telomeres in nevi (Michaloglou et al., 2005) casting doubt on the validity of the telomere 
hypothesis. 
In a 2009 study, Haferkamp and colleagues returned to the role of the CDKN2A locus 
genes in mediating growth-arrest downstream of aberrant MAPKinase signaling.  The group 
transduced primary human melanocytes with a lentiviral NRASQ61K transgene and observed a 
strong upregulation of the DDR pathway including increased phosphorylation of CHK2 and p53, 
similar to that seen by DiMicco et al with HRASG12V.  In concordance with Michaloglou et al., they 
also observed concurrent upregulation of p16INK4A protein downstream of aberrant MAPKinase 
signaling.  Overexpressing p16INK4A transgene in WMM1175 melanoma cells, they found that p16 
induced upregulation of senescence markers, such as Senescence-Associated Beta 
Galactosidase (SA-B-Gal) staining and senescence-associated heterochromatin foci (SAHF).  
Consistent with Michaloglou’s findings, Haferkamp ultimately concluded that regulation of RB 
phosphorylation by p16 contributed more to inducing growth arrest than did p53 upregulation 
(Haferkamp et al., 2009).   
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While these publications established relationships between activating mutations in RAS 
and BRAF and the growth arrest phenotype observed in nevi, as well as p16 expression, they 
raised further questions.  What is the molecular connection between BRAFV600E and the CDK 
inhibitors?  Do the effects of exogenous BRAFV600E or p16 overexpression change in different cell 
types such as melanocytes?  How does exogenous BRAFV600E overexpression affect proliferation 
in human melanocytes, the cell of origin of melanoma?  To explore these unanswered questions 
we sought to isolate benign human nevi and test these hypotheses directly. 
 
 
Part 2: Role of CDKN2B in BRAFV600E-mediated growth arrest. (Pre-Thesis Contribution) 
(Reproduced from McNeal et al. Cancer Discovery 2015).  
BRAFV600E Nevus Melanocytes are Growth-Arrested 
To better understand the mechanisms promoting growth arrest in BRAF(V600E) nevi, we 
set out to first isolate nevus melanocytes.  Melanocytes from clinically benign nevi were excised 
from 27 human donors (Fig. 2.1A).  To ensure that our nevus cells were growth arrested and not 
contaminated with cells already progressing to melanomas, we specifically used long-standing 
nevi with benign appearance and no history of recent morphologic changes were collected.  
Interestingly, we found that cultured nevus-MCs were morphologically indistinguishable from 
melanocytes isolated from unremarkable skin (Fig. 2.1B).  Sequencing BRAF cDNA from cultured 
nevus-MCs revealed overlapping, equal-intensity peaks at nucleotide 1799, corresponding to 
expression of both wild-type (1799T) and mutant V600E (1799T>A) BRAF alleles (Fig. 2.1C).  
Keratinocytes isolated from epidermis associated with the nevi expressed only wild-type BRAF 
(Fig. 2.1C).  While nevus-MCs remained viable in vitro, they failed to proliferate, independent of 
cell plating density, reflecting their in vivo growth-arrest.  Consistent with this, the Ki-67+ 
proliferative index of nevus-MCs was only 4%, compared to 38% for normal MCs, (Fig. 2.1D).  To 
determine whether BRAF(V600E) expression was sufficient to drive MC proliferative arrest in the 
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absence of additional in vivo cues, we engineered normal primary melanocytes to express 
doxycycline-inducible BRAF(V600E) (diBRAF(V600E)).  Consistent with a key role for 
BRAF(V600E) in nevus-MC growth arrest, doxycycline treated diBRAF-MCs ceased to proliferate, 
while untreated diBRAF cells proliferated normally (Fig. 2.1E). 
 
 
 
 
Figure 2.1: BRAFV600E-Driven Melanocyte Growth Arrest.  
(A) Clinical image of a benign nevus used in this study.  
(B) 10× brightfield images of representative normal-MCs (left) and nevus-MCs (right). Scale 
bars = 20μm.  
(C) Sanger sequencing of nevus-associated keratinocytes expressing WT BRAF (left), and 
nevus-MCs expressing BRAF(V600E) (right).  
(D) Ki-67 proliferation index of normal and nevus-MCs.  
(E) Growth of diBRAF melanoctyes +/− 0.25μg/mL doxycycline showing proliferation arrest in 
BRAF(V600E)-expressing MCs.  
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(F) Relative mRNA expression of cell cycle regulators in normal vs nevus-derived melanocytes. 
*P<0.05. n = 3 biological replicates of distinct normal and nevus melanocyte populations used in 
each experiment. 
 
 
 
The Cyclin Dependent Kinase Inhibitor p15 is Induced in Nevi 
To elucidate the mechanisms underlying BRAF(V600E)-induced growth arrest, we 
compared expression of cell cycle regulatory genes in nevus vs normal-MCs by quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR) analysis. This revealed increased 
expression of multiple cell CDKi cycle regulators, the most prominent being CDKN2B (p15) (Fig. 
1F). We further confirmed that, benign human nevi in vivo also express high levels of p15 (Fig. 
2.2A and 2.2B).  Conversely, epidermal melanocytes in adjacent tissue, not associated with the 
nevus, appeared p15 negative (Fig. 2.2C and 2.2D).  p15 has been shown to inhibit CyclinD-
CDK4/6 complexes, and promote Rb-dependent maintenance of the G1-S cell-cycle checkpoint 
(Hannon et al. 1994) (Hannon and Beach, 1994).  We therefore hypothesized that p15 may play 
a role in arresting nevus growth, potentially cooperating with other upregulated cell cycle 
regulators including p14, p16, and p21 to maintain proliferative arrest in vivo. To test the 
hypothesis that p15, and/or p16, induction is a necessary component for BRAF(V600E) growth 
arrest, and to determine whether the growth arrest is reversible, we first sought to circumvent 
p15/p16 function through expression of CDK4(R24C) in arrested nevus, and diBRAF(V600E) 
melanocytes (Wolfel et al., 1995) (Zuo et al., 1996). We found that the R24C mutation renders 
CDK4 resistant to p15/p16 inhibition, and restored proliferation in both nevus and engineered 
diBRAF(V600E) MC. 
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Figure 2.2: p15 Expressed in Nevi is a Key Factor Mediating BRAF Growth Arrest.  
(A) p15 expression in a benign intradermal nevus and (B), antibody control (C), Co-
Immunofluorescence of p15 and Melan-A in a representative intradermal benign nevus. Scale 
bars = 100μm.  
(D) Nevus melanocytes express p15, whereas non-nevus melanocytes (white arrows) are p15-
negative.  Scale bar = 25uM. 
 
 
 
Figure 2.3: Active CDK4 reverses BRAFV600E-mediated melanocyte growth arrest. 
(A) Ki-67 expression (green) of nevus MC (left) and nevus MCs transduced with CDK4(R24C) 
(right) on chamber slides.  Sections were counterstained with Mel-A (red) and DAPI (blue). 
(B) Percent Ki-67 positive cells in normal MCs, nevus MCs, and nevus MCs expressing 
CDK4(R24C).  n = 3 biological replicates per experiment. *P<0.05. Scale bars, 10µm. 
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(C) Relative proliferation of diBRAF(V600E) MCs transduced with either a luciferase control 
(Luci) or activated CDK4 (CDK4(R24C)), and treated with or without 0.25µg/mL doxycycline.  
Values reflect the average ± SEM of n = 3 biological replicates. 
 
 
p15 Induction by BRAF is Both Sufficient and Necessary for Melanocyte Growth Arrest 
 
To test whether expression of BRAF(V600E) is sufficient on its own to upregulate p15 and 
p16, we compared their expression in doxycycline treated diBRAF(V600E)-MCs, nevus-MCs, and 
normal MCs. Whereas normal MCs expressed very little p15 or p16, doxycycline treated diBRAF-
MCs and nevus-MCs both expressed p15 and p16 at high levels in primary culture and in vivo. 
(Fig. 2.3A-D).  Extended culture of primary nevus-MCs in vitro showed that elevated levels of p15 
and p16 were maintained along with the growth-arrested phenotype. Importantly, p15 induction 
and the associated growth arrest are both dependent on the level of BRAF(V600E) expression. 
Levels of p15 initially increase proportionally with increasing BRAF(V600E) protein. However, at 
the highest doxycycline-induced BRAF levels, or with high-level BRAF-expression driven by a 
conventional lentivirus utilizing a constitutive PGK promoter, p15 protein induction is attenuated, 
and melanocytes continue to proliferate (Fig. 2.4A).  This highlights the need to consider BRAF 
protein levels when using model systems, and led us to rely on the native nevus cells for functional 
in vivo experiments.  To determine whether p15 is sufficient to cause MC growth arrest without 
simultaneous induction of other growth regulators including p16, we transduced primary 
melanocytes with p15 or p16. Melanocytes expressing p15 halted proliferation, while MCs 
expressing p16 continued to divide, albeit more slowly than controls (Fig. 2.4B). Through virus 
titering and quantitative PCR, we demonstrated that these proliferation differences did not result 
from relatively lower levels of p16 gene expression.  The relative proliferation effects correlated 
well with p-Rb protein, with p-Rb levels lowest in the p15 expressing melanocytes. Although p15 
and p16 share structural homology through their ankyrin repeat domains, there are significant 
regions of divergent sequence, particularly in the N-terminus, that may serve to make p15 a more 
efficient CDK inhibitor (reflected by lower p-RB). 
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Additionally, previous work using a series of cell lines and chimeric p15/p16 domain swap 
constructs established that sequences unique to the p15 N-terminus confer p15 with the ability to 
influence cell cycle beyond Rb, and that p16 does not possess this activity (Aytac et al., 1999). 
While the specific interacting proteins and pathways mediating this additional p15 activity are not 
yet established, they are likely functionally important in nevus melanocytes.  To test whether 
BRAF(V600E)-induced growth arrest requires p15 or p16, we transduced diBRAF(V600E) cells 
with shRNAs targeting p15 (p15i) or p16 (p16i) (Fig. 2.4C and 2.4D). Without doxycycline, 
diBRAF(V600E) cells harboring p15i or p16i proliferated normally as expected. With doxycycline, 
proliferation of diBRAF(V600E) cells expressing control or p16i slowed dramatically, while p15i 
cells continued to proliferate. Together, these data indicate that p15 is both necessary and 
sufficient for BRAF(V600E)-mediated growth arrest. To ensure that the observed proliferation 
phenotype of the p15 knockdown was due to loss of p15 and not an off-target effect of the shRNA, 
we restored p15 expression in diBRAF(V600E) melanocytes expressing the p15 shRNA, and 
demonstrated that cells again growth arrested as expected. As an additional control, we also 
validated the phenotype using a CRISPR-Cas9 approach targeting the CDKN2B locus. As with 
shRNAs targeting p15 mRNA, CDKN2B ablation by CRISPR-Cas9 prevented BRAF(V600E)-
induced growth arrest.  As CDKN2A and CDKN2B are frequently simultaneously deleted in 
melanoma, we next investigated whether simultaneous loss of p15 and p14/16 activity had an 
additive effect on overcoming BRAF(V600E) growth arrest. We utilized the melanoma-associated 
dnp53 mutant (R248W) to recapitulate the functional effects of p14 loss. Accordingly, we 
compared the relative proliferation of diBRAF(V600E) melanocytes expressing shRNAs targeting 
p15, to matched cells with the p16 shRNA and dnp53, or the combination of p15 and p16 shRNAs 
and dnp53. In the absence of BRAF(V600E) expression, all cell populations proliferated normally, 
indicating that there were no off-target effects that compromised general cell cycle regulation. As 
seen previously, melanocytes expressing BRAF(V600E) growth-arrested, while BRAF(V600E) 
cells with p15 knockdown proliferated, albeit more slowly than normal controls lacking 
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BRAF(V600E). BRAFV600E-expressing cells with p16 knockdown and dnp53 expression failed 
to proliferate. However, cells with the combination of BRAF(V600E), p15/p16 knockdown, and 
dnp53 proliferated faster than the cells with p15 knockdown alone.  Therefore, the combinatorial 
loss of p15, p14 (through dnp53) and p16 activity promoted proliferation in the face of 
BRAF(V600E) to a greater extent than the loss of the individual elements. These results are 
consistent with our data showing that while each of the proteins encoded by the 
CDKN2A/CDKN2B locus are important in melanomagenesis, p15 is an especially important 
mediator of the BRAF growth arrest. 
 
Figure 2.4: p15 is Necessary and Sufficient to Arrest Melanocyte Proliferation.  
(A) Western blot analysis of BRAF, p15, and p16 expression in diBRAF(V600E) melanocytes in 
response to increasing levels of doxycycline. β-Actin was used as a loading control.  
(B) Proliferation of normal human melanocytes engineered to express p15 or p16.  
(C) Proliferation of diBRAF(V600E) melanocytes with non-silencing control (NSi), p15 (p15i) or 
p16 (p16i) shRNA knockdown, without (left) or with (right) 0.25μg/mL doxycycline. Data are 
shown as average ± SEM for B and C. n = 3 biological replicates for each group.  
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(D) Western blot analysis of BRAF, BRAF(V600E), p15, and p16 in diBRAF(V600E) cells with 
non-silencing control (NSi), p15 (p15i), and p16 (p16i) shRNA knockdowns. β-Actin was used as 
a loading control. Western blot results and growth curves were representative of three biological 
replicates composed of distinct melanocyte populations. 
 
 
 
p15 is Diminished in Melanoma 
To discover whether p15 helps restrain the oncogenic activity of BRAF(V600E) in vivo, we 
examined informative clinical cases of matched nevi with adjacent melanomas (Fig. 2.5A).  p15 
protein was diminished in the malignant melanomas compared to adjacent nevi (Fig. 2.5B and 
2.5C).  We also examined a series of 12 additional randomly selected malignant melanomas and 
15 benign nevi, along with 5 nevus-melanoma cases and found that the majority of nevi strongly 
expressed both p15 and p16, while the majority of melanomas showed very low to undetectable 
p15 and p16. This pattern of coordinate regulation of p15 and p16 is consistent with the latest 
Cancer Genome Atlas analysis of 278 melanomas in which 93% of melanomas with homozygous 
deletion of CDKN2A (p16) also harbor homozygous deletions of CDKN2B (p15) (Cerami et al., 
2012); (Gao et al., 2013)).  Simultaneous loss of these two cell cycle inhibitors likely reflects the 
close proximity of the adjacent CDKN2A/CDKN2B loci on chromosome 9p21.3. Importantly, the 
TCGA series includes a tumor in which CDKN2B is lost while p16 remains intact, a genetic event 
that has also been described in other series (Glendening et al., 1995). Consistent with these 
previous reports, we also identified a clinical case in our sample group in which a p16 positive 
melanoma developed in the epidermis overlying a benign nevus.  While the nevus melanocytes 
robustly expressed both p15 and p16, the melanoma retained only p16, and lacked p15 
expression. Together these findings highlight the functional importance of p15 loss in human 
melanoma, and suggest that p15 expression may serve as a clinically useful tool to help 
distinguish between benign and malignant melanocytic neoplasias that are otherwise 
histologically ambiguous. 
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Figure 2.5: BRAF-Induced p15 is Decreased in Melanoma.  
(A) Representative clinical image from n = 5 cases in which melanoma developed in continuity 
with a pre-existing nevus.  
(B) p15 expression is markedly diminished in the malignant proliferative nests of the melanoma 
portion of (A) compared to (C) the benign nevus portion. Scale bars, 100μm. 
 
 
BRAF(V600E) Activates p15 Expression Through TGFβ Signaling 
In other cell contexts TGFβ/SMAD activity induces p15 expression (Hannon et al. 1994 ; 
Seoane 2001).   We questioned whether BRAF(V600E) induced TGFβ expression in human 
melanocytes and found that BRAF(V600E) increased both TGFβ mRNA and protein secretion in 
nevus and diBRAF(V600E) melanocytes. (Fig. 2.6A and 2.6B).  To determine whether TGFβ was 
sufficient to recapitulate the anti-proliferative effects of BRAF(V600E), we added TGFβ to primary 
MC cultures. As expected, this induced p15 and arrested growth (Fig. 2.6C).  p15 induction 
resulting from either exogenous TGFβ or BRAF(V600E) is dependent on the TGFβ receptor, as 
the TGFβ receptor inhibitor SB-431542 blocked p15 induction in both cases (Fig. 2.6D). These 
data are consistent with human nevus tissue, which displays robust SMAD activation (Lo et al. 
2008).  The specific transcription complexes downstream of BRAF responsible for directly 
activating TGFβ transcription are not definitively established, but are likely to include EGR-1. 
EGR-1 has been shown to bind TGFB promoter regulatory domains in other human cells (LIu et 
al., 1996) (Baron et al.), and EGR-1 is a firmly established ERK 1/2 target (Ben-Chetrit et al., 
2013). Consistent with these prior studies, EGR-1 was upregulated in BRAF(V600E) nevus 
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melanocytes.  Also consistent with this ERK-dependent p15 induction, inhibition of ERK signaling 
by the MEK inhibitor U0126 blocked BRAF-driven p15 induction. 
We next sought to determine whether inhibiting BRAF(V600E) itself would restore 
proliferation in melanocytes harboring constitutively active BRAF. We treated both our engineered 
doxycycline inducible diBRAF(V600E), and primary nevus derived V600E melanocytes with the 
selective BRAF(V600E) small molecule inhibitor PLX4720. As expected, PLX4720 treatment, 
when delivered with doxycycline to diBRAFV600E cells, prevented both p15 induction and the 
corresponding growth arrest.  In contrast, when the inhibitor was delivered to diBRAF cells in 
which growth arrest had been previously established by antecedent doxycycline administration, 
cells remained growth arrested, and p15 levels remained higher than in normal cells.  This 
suggests that under in vitro culture conditions, BRAF activity and the corresponding p15 induction 
are necessary for establishing the growth arrest, but that additional events may also serve to 
reinforce and maintain it.  Though unexpected, the finding of persistent growth arrest despite 
BRAF(V600E) inhibition is consistent with clinical observations, in which vemurafenib-treated 
patients do not typically display obvious morphological changes in preexisting benign nevi.  Also 
consistent with this, is our observation that PLX4720 does not reverse growth arrest in primary 
melanocytes isolated directly from nevus specimens.  Additionally, we found that melanocytes 
expressing inducible BRAF(V600E) that underwent growth arrest after 3 days of doxycycline 
administration, and were subsequently cultured in media lacking doxycycline, remained growth 
arrested.  This reinforces the idea that melanocytes may employ additional BRAF-independent 
mechanisms that maintain the growth-arrested state, once established. 
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Figure 2.6: TGFβ Secretion Induces p15 Expression and Drives Melanocyte Growth 
Arrest. (A) Relative transcription of TGFβ-1, TGFβ-2, and TGFβ-3 in nevus MCs and normal 
MCs determined by TaqMan qPCR. n = 3 biological replicates for normal MC and n = 4 
biological replicates for nevus MC. *P<0.05.  
(B) TGFβ levels in culture media from diBRAF(V600E) or normal melanocytes. Data are shown 
as average ± SEM, n = 3 biological replicates for diBRAF(V600E) MCs and normal MCs.  
(C) Proliferation of luciferase-transduced melanocytes with or without 100pM exogenous TGFβ. 
Data are shown as average ± SEM. n= 3 biological replicates for each group. 
(D) 100pM TGFβ or BRAF(V600E) driven p15 induction is inhibited by 50μM SB431542 TGFβ 
receptor blockade in human melanocytes. 
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p15 Loss Reverses Nevus-MC Growth Arrest In Vivo and Promotes Progression to 
Melanoma 
 
Finally, to determine whether p15 loss promotes progression from benign nevus to 
melanoma, we transduced nevus-MCs with shRNA targeting p15 (p15i), or control shRNA (NSi), 
dnp53, and hTERT and seeded them with normal human keratinocytes on native human dermis.  
Xenografts were harvested at 60 and 100 days. At 60 days post grafting, nevus-MCs harboring 
anti-p15 shRNAs proliferated to form nests of melanocytes at the dermal-epidermal junction. 
Conversely, nevus-MCs harboring the control hairpin engrafted, but were present only as single 
cells at regular intervals along the basement membrane of the tissue, and did not proliferate into 
melanocytic nests (Fig. 2.7). At 100 days post grafting, nevus-MCs harboring control shRNAs 
maintained their arrested state, while those with p15 knockdown proliferated into large nests, and 
displayed hallmark features of melanoma in situ including large histologically atypical 
melanocytes with high mitotic index and Pagetoid cells migrating upward through epidermis (Fig. 
2.7).  To determine whether loss of p16 was also sufficient to reverse the BRAF(V600E) induced 
growth arrest of nevus-MCs in vivo, we repeated the experiment with nevus-MCs harboring 
shRNAs targeting p16. Consistent with our in vitro data, we found that p16 knock down nevus-
MCs proliferated in the xenograft setting, but did so less robustly than melanocytes lacking p15. 
Loss of p16 led to modest increases in melanocyte density that was intermediate between the 
controls and that of the p15 knockdown tissues. 
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Figure 2.7: p15 Loss Reverses Nevus-MC Growth Arrest and Promotes Progression to 
Melanoma in vivo.  
Hemotoxylin and eosin staining with Mel-A immunofluorescence of Nevus MC expressing 
control shRNA (NSi), dnp53(R248W), and hTert (Row 1), and Nevus MC expressing shRNA 
against p15 (p15i), dnp53(R248W), and hTert (Row 2). Tissue from human skin xenografts was 
harvested at either 60 days (left) or 100 days (right) and is representative of n=3 biological 
replicates. Arrows indicate upward epidermal Pagetoid scattering of neoplastic melanocytes. 
Scale bars = 100μm. 
 
 
 
This work demonstrated the importance of p15INK4B in mediating cell cycle arrest in human 
melanocytic nevi.  Consistent with the observations of Michaloglou et al, these data further 
suggested that while p16INK4A is induced by BRAFV600E, it appears to play a less potent role than 
p15INK4B in establishing growth arrest in melanocytes both in vitro and in vivo.  IF p16INK4A 
upregulation did not potently inhibit cell proliferation in human melanocytes, we questioned what 
it’s role in melanoma progression might be.  To better elucidate the role of CDKN2A gene products 
in the progression from melanocytic nevus to melanoma we sought to directly test the effects of 
CDKN2A loss in human melanocytes and established melanoma cell lines.  
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Part 3: Role of CDKN2A in growth arrest and additional roles in invasion and metastasis. 
 
(Reproduced from Zeng et al. Cancer Cell 2018) 
Targeted engineering of primary human melanocytes 
To explore the consequence of CDKN2A loss in a model that retains both the cell type 
and genome representative of the early stages of melanoma progression, we harnessed CRISPR-
Cas9-mediated homology directed-repair (HDR) to edit the endogenous genetic loci of primary 
human melanocytes. In human melanomas, focal deletions and point mutations in CDKN2A most 
commonly affect exon 2 (Sviderskaya et al., 2003). We therefore designed a strategy to engineer 
a focal replacement of CDKN2A exon 2 with a CMV-promoter driven EGFP (Fig. 8A). Candidate 
sgRNAs for targeting exon 2 were designed and introduced in combination with Cas9 protein into 
normal human melanocytes (NHMs) using an optimized electroporation protocol.  The Cas9 cut 
the expected genome sequence with high efficiency and without notable effects on the top 
predicted off-target sites. We used a double nickase (dCas9) cutting strategy to further reduce 
off-target cutting (Chen et al., 2013) (Ran et al., 2013).  We introduced plasmids expressing each 
sgRNA and dCas9 in combination with a double-stranded template for HDR containing 2 kb 
homology arms. Three weeks after transfection 8–17% of NHMs remained EGFP-positive, 
whereas control cells that received only the HDR template were EGFP-negative (Fig. 8B).  EGFP-
expressing NHMs were isolated via flow cytometric cell sorting (FACS) and compared to sibling 
NHMs with an intact CDKN2A locus (Fig. 8C).  Polyclonal EGFP-expressing NHMs exhibited the 
correct genotype for successful knock-in and the corresponding loss of p16INK4A and p14ARF 
expression, whereas expression of p15INK4B from the CDKN2B locus was retained (Fig. 8D–8E). 
To further validate the specificity of our editing, we expanded three single cell clones and 
performed targeted genome sequencing of over 500 cancer genes.  In each clone, there was only 
one fully-clonal genetic alteration, a bi-allelic CDKN2A deletion (Fig. 8F).  Other alterations were 
present in only small fractions of the clonal populations, implicating CDKN2A editing as likely the 
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only genetic change induced by the engineering event. These data demonstrate that our 
optimized strategy for engineering locus-specific changes in NHMs is both tractable and precise. 
 
 
Figure 2.8: Engineering of CDKN2A null melanocytes. 
(A) Strategy for introducing focal knock-in of CMV-EGFP to replace exon 2 of CDKN2A. 
(B) Percentage of EGFP-positive NHMs three weeks after editing the CDKN2A locus. Data 
represent mean, 25th and 75th percentiles, minimum and maximum values of eight CRISPR 
reactions on three preparations of NHMs. 
(C) Strategy for isolating CDKN2A null NHMs for comparison to wild-type siblings cells. Directly 
after transfection, both Cas9− and Cas9+ conditions contain EGFP+ cells (top). Over time, 
Cas9− cells become uniformly EGFP−, and the remaining EGFP+ cells in the Cas9+ population 
are isolated (middle). Isolated cells are stably EGFP+ and compared to matched EGFP- cells 
(bottom). 
(D) Western blot detection of both CDKN2A protein products (p16INK4A and p14ARF, left) and 
CDKN2B protein product (p15INK4B, right) in isolated EGFP+ and EGFP− NHM populations 
(E) Immunofluorescent visualization of p16INK4A expression in EGFP+ and matched EGFP− 
NHMs. 
(F) Targeted sequencing of three clonal EGFP+ populations to monitor for off-target Cas9 
cutting. Graphed are the mutant allele frequencies of deletions (Del) and point mutations (PM) in 
intergenic, coding and intronic regions.  NHM1–3 refers to independent primary melanocyte 
derivations and engineering events. 
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p16INK4A suppresses melanocyte motility and invasion 
 
We next sought to characterize the oncogenic contributions of CDKN2A loss in primary 
NHMs. CDKN2A deletions were engineered into low-passage neonatal NHMs, as above, and 
compared to CDKN2A wild-type sibling cells. To compare cell behavior in the two sorted 
populations, we utilized digital holographic cytometry, which permits simultaneous quantification 
of cell division, death, senescence, and motility of adherent cells over long-term culture (Fig. 9A) 
(Hejna et al., 2017). Compared to wild-type sibling cells, CDKN2A null NHMs proliferated more 
rapidly and exhibited increased longevity in culture, consistent with previous observations (Obata 
et al., 1997 (Obata et al.) (Sviderskaya et al., 2003) (Sviderskaya, 2002). However, despite 
increased longevity, CDKN2A null NHMs were not immortalized and possessed reduced telomere 
length before undergoing growth-arrest after 60–70 doublings.  Growth-arrest could be rapidly 
induced through transduction of BRAFV600E cDNA as previously reported (Haferkamp et al., 2009); 
(Kumar et al., 2014) (Lu et al., 2016) (Michaloglou et al., 2005). Interestingly, the percentages of 
cells that underwent BRAFV600E-induced growth-arrest were comparable in both CDKN2A null and 
wild-type cells suggesting BRAFV600E overexpression can induce growth arrest in a CDKN2A 
independent manner.   
In addition to the expected effect of CDKN2A loss on cell proliferation, another interesting 
phenotype emerged from our digital holographic analysis. CDKN2A null NHMs were significantly 
more motile compared to wild-type sibling cells (Fig. 9B). To account for movement associated 
with cell division, actively dividing cells were excluded from the analysis, and the increased motility 
remained significant (Fig. 9C). Corroborating these observations, CDKN2A null NHMs also 
exhibited enhanced migration in live-imaged scratch assays (Fig. 9D–9E) and enhanced invasion 
across high-density basement membrane extracts in transwell assays (Fig. 9F).  The increased 
motility of CDKN2A null NHMs was independent of the expression level, intracellular location or 
identity of the fluorescent protein used in the engineering.  To verify the phenotype was the 
consequence of loss of a CDKN2A gene product, we transduced CDKN2A null NHMs with either 
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p14ARF or p16INK4A cDNA. Expression of p16INK4A reverted the motility phenotype, whereas 
expression of p14ARF did not (Fig. 9G). These data demonstrate that the p16INK4A product encoded 
by the CDKN2A locus inhibits cellular motility in primary NHMs. 
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Figure 2.9: CDKN2A loss promotes melanocyte motility and invasion 
(A) Schematic of experimental set-up. For each experiment, NHMs are derived from donated 
tissue and engineered for CDKN2A loss as in Figure 1. After isolation, CDKN2A null and wild-
type sibling cells are monitored via digital holographic cytometry for 72 hr. The rate of cell 
division, motility, morphology, growth arrest and detachment are quantified. Representative 
holographic phase shift images (bottom left) show colored comet tails tracking cells. 
(B) Single cell motility analysis of CDKN2A null NHMs compared to wild-type siblings. Box and 
whisker plot represents mean, 10th, 25th,75th and 90th percentiles of at least fifty cells each 
from three CRISPR reactions of three preparations of NHMs. 
(C) Quantification as in (B) but excluding cells that divided during the 72 hr time period 
surrounding 24 hr of analysis. 
(D and E) Time-lapsed holographic phase shift images (D) and quantification (E) of NHMs 
migrating into scratched region. Yellow line indicates scratch limit at first time point. Error bars 
represent standard deviation of the mean of three CRISPR reactions of three preparations of 
NHMs. 
(F) Quantification of transwell invasion assays where CDKN2A null NHMs and wild-type siblings 
were required to migrate through high-density basement membrane extract. Box and whisker 
plots represent mean, 25th and 75th percentiles, minimum and maximum values of five CRISPR 
reactions of three preparations of NHMs. 
(G) Single cell motility analysis of CDKN2A null NHMs transduced with and sorted for the 
indicated vectors. Box and whisker plot represents mean, 10th, 25th, 75th and 90th percentiles 
of at least fifty cells each from three transductions. 
Asterisks indicate p value of * <0.05 to ***** <0.000005 from unpaired t-test. N.S. indicates no 
significant difference. 
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p16INK4A regulates motility independent of driver mutation 
 
To determine whether CDKN2A loss alters melanocyte motility in the presence of 
melanoma driver mutations, we first engineered wild-type or CDKN2A null NHMs to harbor the 
BRAFV600E point mutation. We transfected ribonucleoprotein (RNP) complexes containing Cas9 
and sgRNA targeting exon 15 of the BRAF locus (Fig. 2.10A). We designed a single-stranded 
(ss)DNA HDR template to introduce the point mutation encoding V600E along with three silent 
mutations that suppress subsequent re-binding of the sgRNA (Fig. 2.10A). To detect mutant 
BRAF, we developed a digital droplet quantitative (dd-q)PCR assay with 100 percent specificity 
for the V600E allele and sensitivity down to 0.1 percent mutant allele frequency (MAF).  Three 
weeks after co-transfection of the RNP with the HDR template into NHMs, 5–9% of the BRAF 
sequences in the culture were mutant.  The MAF of the engineered NHMs increased rapidly in 
standard culture conditions over two months. The resulting populations were ~80% heterozygous 
for BRAFV600E, expressed the BRAFV600E protein, and demonstrated the concomitant increase in 
MAPK signaling. 
After engineering the BRAFV600E mutation into CDKN2A null and wild-type melanocytes 
(Fig. 2.10B), we observed that CDKN2A loss induced motility independent of either BRAF status 
or treatment with vemurafenib (Fig. 2.10C). To further investigate the pervasiveness of p16INK4A-
regulated motility, we obtained ten human melanoma lines representing different driver mutations 
and CDKN2A states (Fig. 2.10D).  CDKN2A null or silenced lines were more motile than lines with 
p16INK4A expression.  Similar to the engineered NHMs, the enhanced motilities of lines that did not 
express p16INK4A were reverted upon ectopic expression of p16INK4A (Fig. 2.10E).  Concordantly, 
motility was increased in all CDKN2A-expressing lines upon targeted p16INK4A knockdown. In 
contrast, the manipulation of p16INK4A did not consistently alter proliferation across each line (Fig. 
2.10F). These data demonstrate that regulation of cellular motility by p16INK4A occurs independent 
of the diver mutation and is not constitutively tied to cellular proliferation. 
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The acquisition of invasive behavior is a critical bottleneck to the series of events that 
occur during metastatic dissemination of melanoma. Previous reports have connected CDKN2A 
loss with metastatic dissemination in mouse model systems, but the mechanism has been 
attributed to indirect effects of p16INK4A on cell cycle regulation or p14ARF on p53-mediated 
apoptosis (Ackermann et al., 2005) (Aguirre, 2003) (Krimpenfort et al., 2001) (Pavey et al., 2002)). 
Since our data connect loss of CDKN2A (specifically p16INK4A) with the acquisition of invasive 
behavior, we chose two lines from our panel to investigate whether p16INK4A loss could directly 
affect the outcome of an in vivo assay for metastatic dissemination, independent of its inhibitory 
role on proliferation. 
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Figure 2.10: p16INK4A regulates motility independent of driver mutation  
(A) Strategy for introducing BRAFV600E point mutation. Center of HDR template is shown 
(blue) with point mutations causing intended codon change (orange) or silent mutations 
disrupting sgRNA binding (green) highlighted. sgRNA sequence shown in purple. 
(B) Western blot detection of BRAFV600E and p16INK4A expression and ERK phosphorylation 
in engineered NHMs. 
(C) Population motility analysis of NHMs engineered with BRAFV600E and/or CDKN2A 
deletion. Error bars represent standard deviation of the mean of three experiments. 
(D) Comparison of motility in ten melanoma lines with different genetic backgrounds. Lines were 
classified by activating driver mutation (BRAF, NRAS, CKIT or Wild-type) and CDKN2A status. 
CDKN2A status was designated as either wildtype and expressed (Wild-type), mono-allelic 
disruption and expressed (Heterozygous), bi-allelic disruption (Homozygous), or wild-type and 
silenced (Silenced). Box and whisker plot represents mean, 10th, 25th, 75th and 90th 
percentiles of forty cells per line. 
(E) Effect of EF1a-driven p16INK4A expression on motility in CDKN2A null or silenced 
melanoma lines (left). Effect of shRNA-mediated p16INK4A knockdown on motility in p16INK4A 
expressing melanoma lines (right). Error bars represent standard deviation of the mean of forty 
cells per condition. 
(F) Comparison of the effect of p16INK4A loss on proliferation and motility in ten melanoma 
lines. Red dots represent comparison of shRNA-mediated p16INK4A knock-down normalized to 
vector controls in p16INK4A expressing melanoma lines. Green dots represent comparison of 
vector controls normalized to EF1a-driven p16INK4A expression in CDKN2A null or silenced 
lines. No significant correlation between proliferation and motility was observed. 
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Asterisks indicate p value of ** <0.005 to **** <0.00005 from unpaired t-test. N.S. indicates no 
significant difference. 
 
 
p16INK4A loss induces metastasis in WM793 melanoma line 
 
The WM793 melanoma line was derived from a BRAFV600E – mutant early stage primary 
melanoma and is immortalized, but does not metastasize when injected subcutaneously into 
immune-compromised mice (Herlyn et al., 1985). In contrast, its derivative line, 1205Lu, 
disseminates to the lung (Juhasz et al., 1993).  To investigate genetic differences between the 
non-metastatic WM793 cell line and its metastatic derivative line 1205Lu, we performed targeted 
sequencing and copy number analysis. Known pathogenic alterations were shared between both 
cell lines, confirming their common ancestry, but each also harbored private point mutations and 
copy number alterations, most of which were not considered drivers (Fig. 2.11A–2.11C).  
However, the metastatic 1205Lu cell line harbored a bi-allelic deletion and associated loss of 
p16INK4A expression, while the WM793 cell line retained a copy of the CDKN2A locus and 
expression of p16INK4A (Fig. 2.11B). 
To assess the effect of p16INK4A expression on metastatic potential, derivative lines of 
1205Lu and WM793 that respectively added back and knocked down p16INK4A were developed. 
Derivative lines were injected subcutaneously into the flanks of immune-comprised mice, and 
lungs were harvested for analysis after 5 weeks (Fig. 2.11D).  Metastasis formation was abolished 
in the p16INK4A-expressing 1205Lu line, and conversely, WM793 cells acquired the ability to 
metastasize to the lung upon p16INK4A knockdown (Fig. 2.11E–2.11H). Despite the increase in 
metastatic potential upon p16INK4A knockdown, the growth rate of the primary tumor at the animals’ 
flank remained low, and we observed no correlation between in vitro or in vivo proliferation rates 
and metastasis (Fig. 2.11I). These data demonstrate that metastatic potential can be gained 
through spontaneous or targeted loss of p16INK4A via a mechanism that is uncoupled from its 
regulation of proliferation. 
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Figure 2.11: p16INK4A loss induces metastasis in WM793 melanoma line.   
(A) A 500 gene panel, comprised of established cancer genes, was used to sequence the 
WM793 and 1205Lu cell lines. Point mutations are stratified by their mutant allele frequencies 
(MAFs) in each cell line as shown. Likely pathogenic mutations are highlighted in red. Data 
points along the diagonal represent mutations shared between the cell lines, and data points 
along either axis represent private mutations. 
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(B) Copy number variation between WM793 and 1205Lu cell lines inferred from sequencing 
depth (top). A focal heterozygous (bottom left, WM793) and homozygous (bottom right, 1205Lu) 
deletion affecting CDKN2A is highlighted in red. 
(C) Phylogenic tree representation of the genetic relationship between the primary WM793 and 
the derivative metastatic 1205Lu cell lines. 
(D) Schematic of experimental setup for metastasis assay. WM793 cells transduced with either 
pSICOR-mCherry or pSICOR-shp16INK4A-mCherry or 1205Lu cells transduced with either 
pHIV-zsGreen or pHIV-p16INK4A-IRES-zsGreen were sorted for fluorescent protein expression 
and injected subcutaneously into NSG mice (n=5 per condition). Primary tumor volume was 
monitored and lung metastasis was analyzed after five weeks. Representative H&E stained lung 
section shows metastasized lesion (right). Red scale bars = 100 µm. 
(E) Representative lung sections with immunofluorescent stain for human nuclear antigen 
(HNA). Red scale bars = 100 µm. 
(F) Quantification of IF images from (E), showing the number of HNA positive cells in the lung 
for each condition (each group represents 100 quantified sections over 5 mice). Box and 
whisker plots represent mean, 10th, 25th, 75th & 90th percentiles. 
(G) PCR amplification of genomic DNA from mouse lungs was performed using human (top) or 
mouse (bottom) specific primers to detect micro-metastases. All lobes were tested and a 
representative experiment is shown. 
(H) Quantification of human specific DNA in murine lung across experiments. Values are 
absolute concentration of human DNA per sample measured via quantitative PCR. Data 
represent biopsies from 20 lung lobes over 5 mice per condition. Horizontal bars represent 
mean. 
(I) Volume of primary tumors for all mice. Error bars represent standard deviation of the mean. 
Asterisks indicate p value of ** <0.005 and **** <0.00005 from unpaired t-test. N.S. indicates no 
significant difference. 
 
 
 
Ultimately, we proposed that loss of p16INK4A promoted melanocyte motility and invasion and 
conferred metastatic capability through activation of the POU3F2 gene that encodes BRN2.  
Although the regulation of BRN2 is complex, we found that in human melanocytes BRN2 
expression is inhibited by p16INK4A - RB interactions and that loss of p16INK4A in the progression to 
invasive melanoma leads to restoration of BRN2 expression. 
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Part 4: Potential regulation beyond the Cyclin Dependent Kinase inhibitors 
 
The research presented in this section helps to clarify the roles of the CDKis p16INK4A and p15INK4B 
in the formation of melanocytic nevi and progression to melanoma.  Despite the initial focus on 
p16 in arresting cell proliferation, we show that p16’s neighboring gene p15 is intimately involved 
in establishing and maintaining growth arrest in melanocytes.  p16 upregulation downstream of 
BRAFV600E signaling likely contributes to the growth arrest of nevus melanocytes, however, bi-
allelic deletion of p16 clearly plays an important role in enhancing the motility and invasive 
capacity of melanoma cells.  Although it might be tempting to “close the file” on nevus growth 
arrest by attributing it to increased p15 and p16 expression, to do so would ignore the vast 
cascade of intracellular changes introduced by BRAFV600E signaling.  As suggested by previous 
research, upregulation of p15 and p16 are two of the many downstream of constitutive BRAF 
activation.  DNA damage induced by hyper replication, depletion of intracellular nucleotide pools, 
and reorganization of chromatin may also play significant roles in establishing or maintaining 
growth arrest.  Additionally, my research into CDKN2B demonstrated an upregulation of many 
CDKi family members, each of which would benefit from a more thorough investigation into their 
roles in cell cycle regulation.  Going forward, it would be helpful to assess each of these events 
in a melanocyte specific cellular context, ideally leveraging the molecular tools afforded by the 
CRISPR revolution, in order to gain greater insight into the formation of melanocytic nevi. 
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Chapter 3: microRNAs Restrain Proliferation in BRAFV600E 
Melanocytic Nevi 
 
(Reproduced from McNeal et al. 2020). 
 
 
Part 1: microRNAs regulate a nevus-specific transcriptome. 
 
Cutaneous melanoma is a potentially fatal skin cancer arising from the pigment-producing 
melanocytes of the basal layer of the human epidermis (Bastian, 2014).  Despite the development 
of targeted therapies, such as small molecule inhibitors and immunotherapy, mortality rates of 
advanced melanoma remain stubbornly high (Siegel et al., 2017).  If detected in its earliest stages, 
however, melanoma can often be cured through surgical excision (Vitiello et al., 2018).  
Acquired activating V600E mutations in the BRAF proto-oncogene drive approximately 
50% of all cutaneous melanomas (Pollock et al., 2003) (Garnett and Marais, 2004).  Yet, when a 
melanocyte acquires a BRAFV600E mutation, the cell does not immediately transform to cancer.  
Instead, it undergoes rapid clonal proliferation followed by growth arrest resulting in a stable 
pigmented skin macule known as a benign nevus or mole (Robinson et al., 1998) (Yeh et al., 
2013).  Despite the continued expression of BRAFV600E, the majority of nevi remain innocuous for 
the lifespan of the individual, suggesting that nevus cells have robust intrinsic defenses against 
hyperproliferation.   
Aberrant MAPKinase signaling downstream of BRAFV600E produces a cascade of 
intracellular changes, each of which may contribute to the establishment and/or maintenance of 
growth arrest.  BRAFV600E expression has been shown to induce negative feed-back loops that 
ultimately dampen MAPKinase signaling (Uribe et al., 2006).  DNA hyper-replication from 
oncogenic activation can simultaneously deplete cellular nucleotide pools and trigger DNA 
damage response pathways (Aird et al., 2013) (Di Micco et al., 2006).  Epigenetic remodeling of 
chromatin observed in nevi can silence key transcriptional targets stymying proliferation (Stolz et 
al., 1991).  Increased gene expression of cyclin dependent kinase 4/6 (CDK4/6) inhibitors, such 
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as p16INK4A and p15INK4B, is also associated with benign nevi (Michaloglou et al., 2005) (McNeal 
et al., 2015) (Zeng et al., 2018).  
Although each of these factors likely contributes to the growth arrest phenotype of stable 
melanocytic nevi, the mechanisms that drive the bi-phasic process of nevogenesis – temporary 
proliferation prior to growth arrest - remain elusive.  DNA sequencing of human nevi revealed that 
proliferating BRAFV600E melanocytes have no additional genetic changes that distinguish them 
from growth-arrested nevus melanocytes (Shain et al., 2015), suggesting that transcriptional 
regulation is crucial for establishing the bi-phasic phenotype and ultimately restraining 
hyperproliferation. Interestingly, the growth restraint itself is non-permanent.  Outside the context 
of transformation, nevus melanocytes can re-enter the cell cycle following exposure to specific 
stimuli, as seen in cases of recurrent nevi (King et al., 2009) or widespread nevus eruption (Burian 
and Jemec, 2019).  Further, it remains unclear how the known mechanisms governing nevus 
growth arrest are overcome during melanoma initiation. For example, while p16INK4A is expressed 
in the majority of nevi, >80% of melanoma in situ outgrowths from nevi and 40% of advanced 
melanomas retain its expression (Zeng et al., 2018) (Funk et al., 1998) (Keller-Melchior et al., 
1998) (Reed et al.) (Talve et al.) (Wang et al., 1996).  Insight into the mechanisms that distinguish 
BRAFV600E-driven melanocyte expansion, growth arrest, and escape could reveal new 
approaches for detection, prevention, and therapeutic intervention in melanoma.  
A unifying characteristic of BRAFV600E-induced growth arrest pathways is the remodeling of 
the melanocyte transcriptome, which must remain durable to prevent nevus transformation to 
melanoma.  microRNAs are small non-coding RNAs that regulate networks of genes and confer 
robustness to transcriptional programs (Ebert and Sharp, 2012). Aberrant microRNA expression 
has been reported in numerous human cancers, including melanoma, where they have been 
shown to play both oncogenic and tumor suppressive roles (Georgantas et al., 2014) (Nemlich et 
al., 2013) (Kanemaru et al., 2011) (Forloni et al., 2014).  microRNAs regulate biological processes 
through complementary binding to the 3’ untranslated region (3’ UTR) of mRNA networks, and 
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therefore can serve as useful probes for unraveling complex transcriptional programs (Melton et 
al., 2010) (Judson et al., 2013) (Pencheva et al., 2012) (Levy et al., 2010).  Seminal studies of 
gene networks targeted by miRNAs specific to aggressive melanoma revealed mechanisms 
required for metastatic dissemination (Pencheva et al., 2012).  Here, we have taken a similar 
approach to unravel the mechanisms driving nevogenesis and melanoma initiation.  Using clinical 
specimens of human nevi with adjacent melanoma, and primary human melanocytes derived from 
both normal skin and nevi, we identified elevated MIR211-5p and MIR328-3p expression as part 
of a nevus-specific transcriptome.  Expression of both microRNAs mediates BRAFV600E - induced 
growth arrest by regulating networks of dozens of genes.  Both microRNAs converge to inhibit 
aurora kinase B (AURKB) translation, which is required to induce growth arrest in BRAFV600E 
melanocytes and melanoma cells.  In turn, we demonstrate that MIR211-5p and MIR328-3p 
regulation of AURKB plays a crucial role in human nevus formation and that their loss permits 
progression to melanoma. 
 
 
Part 2: Role of MIR211-5p and MIR328-3p in Human Melanocytes and Nevus Formation. 
 
Identification of nevus-enriched microRNAs 
We sought to characterize a miRNA program specifically expressed in nevi, as compared 
to healthy melanocytes or melanoma arising from nevi (Fig. 3.1A). To first identify miRNAs down-
regulated during transformation, we analyzed small RNA-sequencing from a previously 
established cohort of nevus with adjacent melanoma.  Melanocytic nevus and melanoma portions 
of each case were isolated and subjected to targeted exon, mRNA, and small RNA sequencing  
(Shain et al., 2018) (Torres et al., 2020) (Fig. 3.1B).  For each case, the nevus component was 
phylogenetically confirmed as a precursor to the adjacent melanoma (Shain et al., 2018).  All 
lesions shared the BRAFV600E driver mutation.  We performed differential expression analysis 
using the DESeq2 R package (Love et al., 2014) to determine which microRNAs consistently 
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presented altered expression in the melanomas as compared to the precursor nevi.  The analysis 
revealed a cohort of microRNAs exhibiting elevated expression in the nevus tissue, but down-
regulated in the adjacent melanoma tissue, including MIR125b-5p, MIR100-5p, MIR328-3p, 
MIR211-3p, MIR125a-5p, and MIR211-5p (each p-value adjusted for multiple test correction of 
<0.05) (Fig. 3.1C).  These observations are consistent with previous studies that have identified 
MIR125b-5p, MIR100-5p, and MIR211-5p as enriched in nevus tissue as compared with adjacent 
melanoma (Holst et al., 2011) (Damsky et al., 2015) (Levy et al., 2010).  Likewise, our study 
confirmed previous reports identifying MIR21-5p as a melanoma-enriched microRNA 
downregulated in adjacent nevi (Wandler et al., 2017).   
To probe for nevus-specific expression, as compared to normal human melanocytes, we 
next isolated melanocytes from fresh biopsies of long-standing nevi with no history of 
morphological change (n = 6) or healthy human skin with no visible melanocytic neoplasia (n = 8) 
(Fig. 3.1D-E).  Sanger sequencing confirmed that melanocytes from healthy skin had two wildtype 
BRAF alleles while nevus melanocytes were heterozygous for the mutant BRAFV600E allele 
(T1799A) (Fig. 3.1F).  We then performed small- RNA sequencing on these samples.  Differential 
expression analysis identified MIR125B-5p, MIR100-5p, MIR328-3p and MIR211-5p as increased 
in BRAFV600E nevus melanocytes vs. BRAFWT (p<0.05) (Fig. 3.1G). Taken together, these results 
suggest these miRNAs form part of a nevus-specific transcriptome that increase in expression 
with the establishment of the nevus state then decrease upon transition to melanoma.  
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Figure 3.1: Identification of nevus- enriched microRNAs. 
(A) Schematic highlighting plastic nature of BRAFV600E nevus associated growth arrest and 
putative nevus specific transcriptional program.  
(B) H&E of representative nevus to melanoma transition case with higher magnification insets of 
nevus and melanoma portions. 
(C) Heatmap of top nevus and melanoma-enriched microRNAs from small-RNA sequencing of 
transition cases (n = 7 matched biological replicates of nevi and melanoma) (adj. p<0.05). 
(D) Images of biopsies x10 representative photomicrographs.  
(E) Human foreskin-derived melanocytes (top) and human nevus-derived melanocytes (bottom) 
x10 representative photomicrographs.  
(F) Matched sanger sequencing chromatograms. 
(G) Box-Whisker plots of nevus-enriched microRNAs expression in BRAFWT human melanocytes 
(peach, n= 8 biological replicates) and BRAFV600E human nevus melanocytes (tan, n = 6 
biological replicates).  P-values calculated by unpaired T Test. 
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MIR211-5p and MIR328-3p induce growth arrest in human melanocytes.  
To better characterize the effects of nevus-specific miRNAs on human melanocyte 
proliferation, we nucleofected primary human melanocytes with RNA mimics corresponding to the 
mature sequences of MIR125B-5p, MIR100-5p, MIR328-3p and MIR211-5p, as well as non-
targeting control mimics, and assayed proliferation over 7 days.  Nucleofection of MIR211-5p or 
MIR328-3p each led to diminished melanocyte proliferation in comparison to the non-targeting 
control (* = p<0.05) (Fig. 3.2A).  To validate specificity and potency of each mimic, we generated 
dual fluorescence reporters of MIR211-5p and MIR328-3p function (Fig. 3.2B).  When co-
transfected with the targeting microRNA mimics and analyzed via flow cytometry, we observed a 
uniform inhibition of reporter expression, consistent with subtle translational inhibition expected 
from microRNA expression (Fig. 3.2C). 
 
Figure 3.2: Screening and validation of MIR211-5p and MIR328-3p mimics 
(A) Mean and standard deviation for population fold change of melanocytes nucleofected with 
nevus or melanoma-enriched microRNA mimics compared to non-targeting control (MIRControl) 
(n = 3 biological replicates) (p values calculated by unpaired TTest  
* = p<0.05). 
(B) Schematic of microRNA sponge constructs, which serve as both reporters and inhibitors of 
microRNA function. A zsGreen cDNA expressing a 3’ UTR with 7 tandem microRNA binding sites 
is expressed from the CMV promoter, whereas an mCherry that is not under microRNA regulation 
is expressed from the PGK promoter. After transduction, mCherry positive cells are expected to 
express the microRNA inhibitor and the ratio of zsGreen to mCherry provides a read-out of 
functional microRNA expression.  
(C) FACS analysis depicting the zsGreen to mCherry ratio of melanocytes transduced with 
control, MIR328-3p, or MIR211-5p sponges, then nucleofected with MIR328-3p or MIR211-5p 
mimics. Physiological functional expression of the microRNAs is predicted to cause a subtle left-
shift in the distribution, as observed.  
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To determine whether the proliferation defect was due to growth restriction or increased 
cell death, we monitored the effects of MIR211-5p and MIR328-3p on normal melanocyte 
behavior using digital holographic cytometry (DHC).  DHC is a form of quantitative phase imaging 
(QPI) that permits long-term live imaging and assessment of cell division and death with single 
cell resolution (Hejna et al., 2017).  We conducted DHC of nucleofected melanocytes over the 
course of 72 hours beginning at day 4 post-nucleofection.  MIR211-5p and MIR328-3p 
overexpression induced a dramatic decrease in melanocyte proliferation in comparison to the 
non-targeting microRNA control (Fig. 3.3A).  Single-cell analysis revealed only 32.9% and 25.1% 
of MIR211-5p or MIR328-3p expressing melanocytes divided between day 4 and 5 post-
nucleofection, as compared to 85.9% of control cells (Fig. 3.3B).  Growth arrested cells retained 
the appearance of healthy melanocytes, and the DHC analysis yielded no evidence of cell death.  
Growth arrest continued for 6-7 days (Fig. 3.3C-D). EdU uptake decreased with increasing 
concentration of MIR211-5p and MIR328-3p mimic 4 days post- nucleofection, indicating the rate 
of DNA replication was compromised in human melanocytes following MIR211-5p or MIR328-3p 
nucleofection (Fig. 3.3E).  Corroborating these observations, cell cycle profiling demonstrated a 
consistent increase in the number of cells accumulating in S or G2/M phase of the cell cycle 
between days 3 and 7 following microRNA overexpression (Fig. 3.3F and 14G).  In contrast, co-
staining with propidium iodide and annexin V antibody 4 days post-nucleofection revealed no 
significant differences in the percentage of apoptotic melanocytes (Fig. 3.3H).  Taken together, 
we conclude that over-expression of MIR211-5p and MIR328-3p in human melanocytes induces 
a proliferative arrest in the S/G2/M phases of cell cycle.  
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Figure 3.3: MIR211-5p and MIR328-3p induce growth arrest in human melanocytes. 
(A) Representative images from live digital holographic imaging at indicated times post 
nucleofection of indicated microRNA mimics. 
(B) Percent of melanocytes divided between days 4 and 5 post microRNA nucleofection for 
MIR211-5p (green), MIR328-3p (light blue) vs. MIRControl (dark blue).  Digital holographic 
cytometry. 
Line (C) and bar (D) plots of means and standard deviations of population fold change over 7 
days of MIR211-5p and MIR328-3p nucleofected melanocytes vs. non-targeting MIRControl.  
(E) Percent EdU positive cells after 4 days after nucleofection with 1, 2, 4, and 6uM miRNA mimic. 
(MIR211-5p (green), MIR328-3p (light blue) vs. MIRControl (dark blue), n=3 replicates). 
(* = p <0.05, ** = p<0.01, unpaired T test) 
(F) Representative histograms of propidium iodide staining as measured by flow cytometry.  
Percentages reflect percent cells in S or G2/M phases of cell cycle. 
(G) Percent cells in S or G2/M phases of cell cycle 7 days post- nucleofection with MIRControl, 
MIR211-5p, or MIR328-3p. 
(H) Dot plots for Annexin V/PI stain. Barplot of % Annexin V/PI positive cells. (n = 3 biological 
replicates).     
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Endogenous MIR328-3p and MIR211-5p contribute to BRAFV600E-induced growth arrest 
 
Our microRNA profiling of normal and nevus melanocytes and adjacent melanoma 
showed that MIR211-5p and MIR328-3p were enriched specifically in nevi.  Ectopic expression 
of BRAFV600E has been previously shown to induce growth arrest in human melanocytes 
(Michaloglou et al., 2005).  As ectopic expression of MIR211-5p and MIR328-3p also induce 
growth arrest, we reasoned that endogenous expression of these microRNAs might contribute to 
BRAFV600E-induced growth arrest.  To test whether inhibition of endogenous MIR211-5p and 
MIR328-3p expression is sufficient to rescue BRAFV600E-induced growth arrest, we leveraged a 
doxycycline inducible BRAFV600E system (di-BRAFV600E) (McNeal et al., 2015).  We generated low 
passage human melanocytes expressing di-BRAFV600E and exposed cells to doxycycline.  
Western blot analysis showed that the transduced melanocyte population expressed increasing 
levels of BRAFV600E and ERK 1/2 phosphorylation when exposed to increasing concentrations of 
doxycycline (Fig. 3.4A).  As expected, the induction of BRAFV600E decreased proliferation in 
melanocytes from three separate donors (Fig. 3.4B).  Cell cycle analysis revealed a dose-
responsive increase in the S/G2/M phase arrest, similar to the miRNA overexpression (Fig. 3.4C). 
We were initially surprised by this result, as BRAF-driven G1 phase arrest has been reported, but 
closer inspection of these previously published data revealed an unappreciated S/G2/M phase 
arrest, as well (Zhu et al., 1998).  
To determine whether MIR211-5p or MIR328-3p were necessary effectors of BRAFV600E-
induced growth arrest in human melanocytes, we inhibited MIR211-5p and MIR328-3p in 
BRAFV600E melanocytes using two approaches.  First, we nucleofected di-BRAFV600E melanocytes 
with LNA microRNA inhibitors and assayed for Edu incorporation after 4 days.  In the presence 
of a non-targeting control inhibitor, induction of BRAFV600E decreased Edu uptake by 7% (p<0.01).  
In contrast, in the presence of inhibitors targeting MIR211-5p or MIR328-3p, there was no 
significant decrease in mean EdU uptake in melanocytes regardless of BRAFV600E expression 
(Fig. 3.4D).  In parallel, we generated di-BRAFV600E melanocyte lines that constitutively expressed 
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a microRNA sponge containing seven MIR211-5p or MIR328-3p binding sites and mCherry under 
control of independent promoters (Fig. 3.4E).  We then conducted a competition assay between 
mCherry positive (sponge-expressing) and mCherry negative melanocytes.  After five days of 
exposure to doxycycline, the mCherry population of cells expressing control sponge remained at 
constant, whereas the mCherry population of cells expressing sponges to MIR211-5p or MIR328-
3p increased by 44.3% and 21.0%, respectively.  Taken together, these results suggest that 
MIR211-5p and MIR328-3p independently contribute to BRAFV600E-mediated growth arrest in 
human melanocytes. 
 
 
 
Figure 3.4: BRAFV600E induced growth arrest requires MIR211-5p and MIR328-3p. 
(A) Western Blot analysis of BRAFV600E, phospho-ERK1/2 in diBRAFV600E melanocytes in 
response to increasing concentration of doxycycline.  HSP90 was used as a loading control.  
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(B) Population fold change for di-BRAFV600E MCs treated with 62.6 ng/mL doxycycline (paired 
T Test, n=3 biological replicates). 
(C) Percent cells in S or G2/M phases of cell cycle after 7 days exposure to indicated 
concentrations of doxycycline. (* = p <0.05, paired T Test) 
(D) Mean and standard deviation of percent EdU positive diBRAFV600E melanocytes 7 days 
post-nucleofection with MIRControl, MIR211-5p, or MIR328-3p and with (+) or without (-) 
exposure to doxycycline. (** = p<0.01, unpaired T test) (n = 6 biological replicates).  
(E) Schematic of expected (top) and actual (bottom) results (mean and standard deviation) for 
competitive growth assay comparing diBRAFV600E melanocytes grown 13 days with exposure 
to doxycycline with or without mCherry tagged microRNA sponges. (* = p <0.05, ** = p<0.005, *** 
= p<0.0005, unpaired T Test, n=3 replicates) 
 
 
Part 3: Role of AURKB and GPR3 in Progression from Nevus to Melanoma 
AURKB and GPR3 inhibition contributes to BRAFV600E-induced growth arrest 
Previous studies demonstrated that comprehensive characterization of microRNA targets 
can elucidate novel mechanisms in development and cancer progression.  Having identified 
MIR211-5p and MIR328-3p as upregulated in human BRAFV600E nevus melanocytes and 
contributors to BRAFV600E-induced growth arrest, we next investigated the genetic networks 
regulated by MIR211-5p and MIR328-3p that converge to restrain melanocyte proliferation. We 
nucleofected normal human melanocytes with MIR211-5p, MIR328-3p, or non-targeting 
microRNA control mimics.  Four days post nucleofection, we harvested total RNA from each 
sample and performed high-throughput mRNA sequencing.  Computationally predicted targets of 
MIR211-5p and MIR328-3p were enriched among the genes down-regulated by each mimic 
respectively (Fig. 3.5A and 3.5B).  .  The majority of these targets exhibited 2-fold or less 
expression reduction, consistent with the established models of microRNA targeting on transcript 
levels.  
To determine whether any of the downregulated transcriptional targets of the MIR211-5p 
or MIR3238-3p contribute directly to the growth arrest microRNA phenotype, we performed a 
small interfering RNA (siRNA) screen against each target in normal human melanocytes.  We 
tested a total of 131 down-regulated predicted targets of MIR211-5p and MIR328-3p.  Of the 
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siRNAs tested, 86 inhibited predicted targets of MIR211-5p, 23 inhibited predicted targets of 
MIR328-3p, and 6 inhibited predicted targets of both microRNAs (Supplementary Table S1).  The 
effect of each siRNA pool on EdU incorporation was compared to that of six controls: no mimic, 
a non-targeting siRNA control (Scramble 1), 2 non-targeting microRNA controls (Scramble 2 and 
Scramble 3), and MIR211-5p and MIR328-3p mimics.  Knockdown of 62 of the 131 predicted 
target genes resulted in EdU uptake significantly less than that of the siControl (p<0.05), though 
few induced changes as significant as the microRNA mimics themselves ((Fig. 3.5C). . These 
observations are consistent with previous reports that knockdown of individual genes in a 
microRNA target network can only partially phenocopy overexpression of a microRNA (Judson et 
al., 2013).  
 
 
Figure 3.5: Identification of MIR211-5p and MIR328-3p mRNA targets. 
(A) Volcano plots of mRNA sequencing from n = 4 biological replicates of melanocytes 
nucleofected with MIR211-5p (left) or MIR328-3p (right) vs. MIRControl.  (MIR211-5p predicted 
targets = green, MIR328-3p predicted targets = light blue). 
(B) GSEA analysis of MIR211-5p and MIR328-3p target mRNAs. 
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(C) Mean and standard deviation from n = 3 replicates of percent EdU positive melanocytes 
harboring knockdown of predicted MIR211-5p (left) or MIR328-3p (right) targets.  Dark blue bars 
represent no mimic (nucleofection) control and three scrambled controls.  Green bar represents 
MIR211-5p and light blue bar represents MIR328-3p. 
  
 
To further narrow the scope of our study, we focused on genes that were down-regulated 
by both MIR211-5p and MIR328-3p and whereby knockdown significantly impaired EdU 
incorporation.  We reasoned such genes represent potential network nodes where the MIR211-
5p and MIR328-3p target networks converge.  We identified AURKB and G-protein coupled 
receptor 3 (GPR3) as genes with significantly decreased expression upon expression of either 
microRNA (Fig. 3.6A).  AURKB is predicted to be targeted by both MIR211-5p and MIR328-3p, 
whereas GPR3 is a predicted target of MIR328-3p only (Fig. 3.6B).  To investigate whether 
AURKB or GPR3 inhibition is required for the microRNA-induced growth arrest phenotype, we 
generated lentiviral expression constructs for each coding sequence, which lacked the predicted 
microRNA binding sites (Fig. 3.6C and 3.6D).  Human melanocytes stably expressing each gene 
were nucleofected with MIR211-5p, MIR328-3p, or a non-targeting control.  We assayed 
proliferation over 7 days and found that overexpression of AURKB rescued and GPR3 partially 
rescued the MIR211-5p induced growth defect (Fig. 3.6E).  Likewise, AURKB overexpression 
partially rescued the MIR328-3p induced growth arrest, whereas GPR3 overexpression did not 
ameliorate the phenotype. 
To determine whether AURKB or GPR3 expression could rescue the BRAFV600E-induced 
growth arrest in human melanocytes, we overexpressed either AURKB, GPR3, or zsGreen 
transgenes in human melanocytes previously transduced with the di-BRAFV600E transgene.  In the 
absence of doxycycline- induced BRAFV600E expression, AURKB increased melanocyte 
proliferation (Fig. 3.6F).  When BRAFV600E was expressed, AURKB rescued proliferation.  In 
contrast, GPR3 expression decreased melanocyte proliferation, however, when BRAFV600E was 
expressed, GPR3-expressing cells did not further decrease proliferation (Fig. 3.6F).  To validate 
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the finding that AURKB could rescue BRAFV600E-induced growth arrest in vitro, we asked whether 
AURKB was sufficient to restore proliferation to growth arrested human nevi.  We transduced 
non-proliferating nevus melanocytes from three independent donors with lentivirus harboring 
AURKB and mCherry at low MOI.  QPI for 90 hours post-infection demonstrated that nevus 
melanocytes that expressed mCherry (and therefore AURKB) significantly increased proliferation 
in comparison to mCherry negative nevus melanocytes (Fig. 3.6G).  These results further suggest 
that inhibition of AURKB by MIR211-5p and MIR328-3p is essential for the BRAFV600E-induced 
growth arrest in human melanocytes. 
 
Figure 3.6: AURKB and GPR3 inhibition contribute to BRAFV600E-induced growth arrest. 
(A) Normalized read counts for AURKB or GPR3 in melanocytes nucleofected with MIRControl 
(dark blue), MIR211-5p (green), or MIR328-3p (light blue).  P-values calculated by Wilcoxon test 
(n = 4 biological replicates for each condition). 
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(B) Schematics showing potential binding sites of MIR211-5p and MIR328-3p in the 3’ UTRs of 
AURKB (left) and GPR3 (right). 
(C) Western Blot of AURKB expression in human melanocytes with or without lentiviral AURKB 
overexpression.  HSP90 is the loading control. 
(D) Representative photomicrographs (20X) of immunofluorescence for GPR3 (green) or 
(Hoechst) (purple) in human melanocytes with GPR3 lentiviral overexpression (GPR3 OE) or 
without (Control) over-expression. 
(E) Cell number fold change mean and standard deviation for melanocytes overexpressing 
zsGreen control, AURKB, or GPR3 and nucleofected with MIR211-5p (left) and MIR328-3p (right). 
P values calculated by type 2 unpaired T Test. (*= p<0.05) (n = 6 biological replicates).   
(F) Cell number fold change mean and standard deviation for melanocytes transduced with 
doxycycline inducible BRAFV600E and either ZSGreen control, AURKB, or GPR3, and then 
treated with (+) or without (-) dox. (p values calculated by unpaired T-Test and compare to 
ZSGreen (+) or ZSGreen (-) dox respectively *= p<0.05) (n = 6 biological replicates).  
(G) Experimental design (top left) and representative images capturing dividing nevus melanocyte 
(bottom left) and quantification (right) of digital holography of human nevus cells infected with low 
titer AURKB/mCherry lentivirus. (n = 3 biological replicates) (p value calculated by paired T-Test). 
 
 
 
 
Increased AURKB and GPR3 expression are associated with progression to melanoma 
 
Taken together, our results demonstrate that BRAFV600E nevus melanocytes express 
increased levels of MIR211-5p and MIR328-3p, and that these microRNAs contribute to growth 
arrest through inhibition of AURKB and GPR3.  If true, we would expect that the expression of 
these genes would be elevated in melanoma as compared to nevi. Transcriptional profiling of nevi 
(n = 11) and adjacent melanoma (n = 12) from human FFPE tissue revealed that AURKB and 
GPR3 transcripts are significantly upregulated in melanoma in comparison to nevi – an inverse 
expression pattern of MIR211-5p and MIR328-3p (Fig. 3.7A Immunohistochemistry (IHC) of 
human nevus (n = 11) and melanoma (n = 11) sections further demonstrated that AURKB and 
GPR3 expression is upregulated in melanomas relative to nevi (Fig. 3.7B).  If upregulation of 
either gene were also essential for melanoma growth, we would further expect that inhibition 
would revert BRAFV600E melanoma cells to a growth-arrested state.  Two BRAFV600E human 
melanoma cultures – one established line (501MEL) and one derived from a low passage patient-
derived xenograft tumor (HCIMel019) – were treated with the selective AURKB inhibitor, 
Barasertib (Helfrich et al., 2016). Both cultures were highly sensitive to the compound, consistent 
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with a previous report (Fig. 3.7C) (Porcelli et al., 2015).  Live DHC imaging revealed no evidence 
of cell death, but rather growth arrest coupled to significantly increased cell volume, consistent 
with known functions of AURKB (Fig. 3.7D-E). 
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Figure 3.7: AURKB expression promotes melanoma growth. 
(A) Normalized read counts for AURKB (left) and GPR3 (right) expression in matched nevi and 
adjacent melanoma (n = 11 nevi and 12 matched melanomas) (p values calculated by Wilcoxon 
test). 
(B) Representative images (top) and quantification (bottom) of immunohistochemical staining for 
AUKRB (brown chromagen) and GPR3 (red chromagen) expression in FFPE samples of nevi 
and melanoma.  (n = 11 each group). 
(C) Dose response curves for established human melanoma cell line (501MEL) and primary 
human melanoma culture (HCIMel019) treated with AURKB inhibitor, barasertib.  
(D) Representative digital holographic images of HCIMel019 treated with DMSO control or 300 
nM barasertib. 
(E) Quantification of cell volume 48 hours after treatment with indicated concentrations of 
barasertib (n=3 replicates, * = p <0.05, ** = p<0.01, unpaired T test). 
 
 
 
 
 
 
 
 
 
Part 4: Discussion of the role of microRNAs in nevus formation and progression to 
melanoma. 
 
A long-standing question in the field of melanoma biology asks: how are nevi formed?  A 
single mutation – BRAFV600E – drives temporary proliferation followed by subsequent growth 
arrest, but the mechanisms that underlie this bi-phasic phenotype remain opaque.  Equally 
perplexing is the conditional nature of growth arrest induction, wherein incompletely excised nevi 
can regrow to their former dimensions (King et al., 2009), or established nevi can erupt in 
response to external stimuli (Burian and Jemec, 2019).  The mechanisms that permit these events 
are as ambiguous as nevogenesis itself and require that the growth-arrest phenotype be both 
recurrently plastic and durable. Such reversible characteristics are more likely to be associated 
with environmental or transcriptional changes, rather than genetic.  Here we identified two 
microRNAs that are elevated specifically in growth-arrested nevi and are both necessary and 
sufficient for BRAFV600E-induced growth arrest in vitro.  The microRNAs are downregulated, and 
their target expression increases in melanoma arising from nevi.  Previous studies using 
melanoma cell lines representative of the advanced disease have identified MIR211-5p as either 
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a tumor suppressor or an oncomir, dependent on context (Vitiello et al., 2017) (Bell et al., 2014) 
(Levy et al., 2010) (Díaz-Martínez et al., 2018) (Golan et al., 2019) (Sahoo et al., 2019) (Mazar et 
al., 2016) (Mazar et al., 2010).  Our data demonstrate that in the context of primary human 
melanocytes with little to no mutational burden, the transcriptional activation of MIR211-5p and 
MIR328-3p are at least partially responsible for nevus-associated growth arrest and that 
melanoma initiation from nevi requires their subsequent suppression.  
Our data provide evidence that increased expression of MIR211-5p and MIR328-3p 
represent intracellular events that complement previously reported transcriptional changes 
required to establish and maintain growth arrest in nevus melanocytes.  In particular, the genes 
p16INK4A and p15INK4B are potently upregulated in response to BRAFV600E signaling and thought to 
contribute to nevus-associated growth arrest (Michaloglou et al., 2005) (McNeal et al., 2015) 
(Zeng et al., 2018).  Like MIR211-5p and MIR328-3p, expression of both genes can induce 
melanocyte growth arrest in vitro and are frequently lost during transformation to melanoma.  
However, in contrast to inhibition of MIR211-5p and MIR328-3p, inhibition or genetic ablation of 
the CDKN2A locus does not rescue BRAFV600E induced growth arrest (Halaban et al., 1998) 
(Michaloglou et al., 2005) (Haferkamp et al., 2009) (McNeal et al., 2015) (Zeng et al., 2018).  
Similarly, deletion of the locus does not prevent nevogenesis in mouse models (Dhomen et al., 
2009) (Damsky et al., 2015).  Another important distinction is the phase of the cell cycle regulated 
by each gene.  p16INK4A and p15INK4B each inhibit CDK4/6-Cyclin D phosphorylation of RB, leading 
to a G0/G1-S phase cell cycle arrest (Zhang et al., 1999) (Hannon and Beach, 1994).  Conversely, 
MIR211-5p and MIR328-3p block cell cycle progression through S and G2/M phases.  Taken 
together, these observations suggest that microRNA-mediated inhibition of cytokinesis and CDKi-
inhibition of cell cycle entry represent two complimentary mechanisms that each contribute to the 
initiation and the maintenance of growth arrest.  Restriction across multiple stages of the cell cycle 
would enhance the durability of growth arrest in melanocytic nevi, further explaining why so few 
nevi transform to malignant disease over the lifespan of the individual.    The upregulation of 
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multiple cell cycle checkpoints downstream of BRAFV600E may also help explain the difficulties in 
determining a single phase of the cell cycle in which nevus cells are growth-arrested.  Indeed, the 
extent of p16INK4A expression varies across nevus specimens, ranging from no expression, to 
mosaic or uniform expression (Smith et al., 2016). 
We identified expression of MIR211-5p and MIR328-3p as a cell-intrinsic mechanism that 
restrains nevus cell proliferation without the need for further genetic alterations. However, an open 
question remains regarding the upstream mechanism regulating these microRNAs. We favor a 
“two-factor” model, whereby increased expression requires both BRAFV600E and activation of a 
second signaling pathway. In this model, melanocytes that have acquired BRAFV600E would 
proliferate rapidly until the second pathway, and consequently MIR211-5p and MIR328-3p, is 
activated. MIR211-5p has previously been reported to be a transcriptionally regulated by both 
MITF (Levy et al., 2010), and UV exposure (Su et al., 2020) . Future studies determining how 
these microRNAs are regulated in BRAFV600E nevus cells might identify useful therapeutic targets 
for nevus reduction or melanoma prevention.  
Regardless of the cause of their expression, analysis of the mechanism of microRNA 
action, which is pleiotropic and characterized by the simultaneous regulation of networks of target 
genes, has proven a valuable system for probing the mechanisms of cellular transitions (Melton 
et al., 2010) (Pencheva et al., 2012) (Judson et al., 2013).  In this study, we demonstrate that 
MIR211-5p and MIR328-3p converge on AURKB mRNA, the depletion of which is necessary to 
establish both the microRNA-induced growth arrest and BRAFV600E-induced growth arrest in 
human melanocytes.  While AURKB is clearly essential to MIR211-5p and MIR328-3p- mediated 
proliferation arrest, we recognize that AURKB likely represents one of many MIR211-5p and 
MIR328-3p targets that contribute to BRAFV600E-induced growth arrest in melanocytic nevi.  
Indeed, data from our siRNA experiment suggest that depletion of multiple targets each 
phenocopy growth arrest in melanocytes.  Previous studies have identified KCNMA1, TGFBR1, 
TGFBR2, IGF2R, NFAT5, NUAK1, and EDEM1 as MIR211-5p targets in advanced melanoma 
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lines (Mazar et al., 2010) (Levy et al., 2010) (Bell et al., 2014) (Golan et al., 2019) (Vitiello et al., 
2017).  Although we consider the growth suppressive effects of the microRNAs to be the 
summation of target gene network regulation, it is notable that ectopic AURKB expression on its 
own was capable of restoring proliferation in previously growth-arrested patient-derived nevus 
cultures, suggesting this gene is a critical downstream signaling node of these microRNAs in this 
context.  These observations corroborate a previous report that AURKB inhibition is an effective 
therapy in pre-clinical mouse melanoma models (Porcelli et al., 2015), and support further 
development of AURKB inhibitors as a potential adjuvant or therapeutic candidate. 
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Chapter 4: Primary Cilia in Melanocytic Nevi and Melanoma 
 
 
 
Part 1: Biomarkers to distinguish nevi from melanoma. 
 
Thus far this work has focused on defining the intracellular changes induced by BRAFV600E 
signaling that establish and enforce growth arrest in nevus melanocytes.  Understanding the 
cellular mechanisms that contribute to growth arrest is essential to treating melanoma in two 
ways.  First, knowledge of the factors leading to, and maintaining, growth arrest allows 
researchers to exploit potential vulnerabilities in nevus cells and early-stage melanomas to keep 
them from progressing to more damaging disease.  Second, and perhaps more immediately, this 
knowledge enables physicians to better classify nevi and melanoma so as to more effectively 
treat their patients.  Consistently distinguishing between nevi and melanoma, especially in early-
stage lesions, presents a difficult challenge for dermatologists and dermatopathologists.  Current 
techniques involve biopsying lesions, staining with a series of melanocyte and melanoma markers 
and then assessing whether the lesion might pose an immediate threat to the patient.  While these 
practices can often distinguish common nevi from later stage melanoma, it remains difficult to 
reliably separate atypical or dysplastic nevi (nevi with irregular borders) from early stage 
melanoma.  Recently, DNA sequencing and copy number variant (CNV) calling have helped 
resolve difficult cases, however, these approaches are costly to the patient and often less 
accessible to the physician as well as requiring expert interpretation.  Therefore, it is paramount 
that we develop superior biomarkers to distinguish nevi from melanoma in situ.   
Two potential classes of biomarker under active development are microRNAs and the 
primary cilia organelle.  In 2019, Torres et al. published work suggesting that the ratios of 
expression of specific microRNAs could be used to accurately predict whether a lesion was a 
nevus or melanoma.  The study collected RNA from formalin fixed samples of human nevi and 
adjacent melanoma and determined microRNA expression for each case.  The authors then used 
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machine learning algorithms to establish patterns of microRNA expression that best represented 
each type of lesion.  Ultimately, they found that their classification system achieved a sensitivity 
of 81% and a specificity of 88% on an independent cohort of classified lesions.  Remarkably, 
these improved sensitivity and specificity marks were independent of tumor cell content within the 
sample, or the patient’s age - two previously confounding factors in microRNA expression 
analyses (Torres et al., 2020).  microRNAs therefore present a promising diagnostic tool for the 
classification of nevi and melanoma. 
Distinguishing atypical and dysplastic nevi from melanoma in situ is particularly 
problematic, as both lesions possess similar histological features in the epidermis.  The ability to 
biopsy and section and stain these lesions can provide helpful evidence to suggest whether the 
lesion is currently or may progress to malignancy.  However, even with ability to view the cellular 
composition of each lesion under the microscope, it can still be difficult to determine the difference 
between the two.  Current techniques often rely on identifying proliferative markers such as HMB-
45, GP100 (Prieto and Shea, 2011), and S100 family proteins (Nonaka et al., 2008) (Petersson 
et al., 2009).  Interpreting the staining results can be confounded, however, as each section 
represents a single time-point without providing information about the lesion’s evolution.  Are cells 
that stain positive for proliferation markers actively proliferating?  Or do these markers represent 
a period of proliferation that is currently under durable growth arrest?  To resolve these 
complications it is therefore crucial to establish markers that provide a more binary diagnosis of 
malignant vs. benign. 
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Part 2: Primary Cilia Biology 
Primary cilia are an organelle composed largely of microtubules.  These hair-like 
structures project from a single centrosomal centriole known as the basal body.  The centriole 
provides the intracellular base and anchors the primary cilia within the cell membrane.  The 
extracellular component in known as the axoneme and is composed of a ring of 9 microtubule 
doublets.  Although surrounded by the cell membrane, the cilium contains receptor and effector 
molecules that transduce signals from the extracellular environment into the cell (Choudhury et 
al., 2020).   
Despite similar sounding names, primary cilia are distinct from motile cilia in both structure 
and function.  Motile cilia, which can be found on eukaryotic flagella, or on respiratory epithelia 
cells have a similar microtubule structure, but contain an additional two microtubule singlets and 
have dynein arms attached to the outer microtubules.  Unlike motile cilia, primary cilia have no 
known role in cellular movement (Mitchison and Valente, 2017). 
Role of primary cilia in cell signaling 
Given their antenna-like structure and association with signaling molecules, primary cilia 
are thought to transduce extracellular signals to the nucleus.  The signaling role of primary cilia 
has been best defined by their ability to propagate signals in the hedgehog signaling pathway.  
Hedgehog ligands bind to the transmembrane receptors patched 1 (PTCH1) and patched 2 
(PTCH2), which are found on the membrane of the primary cilia.  Smoothened (SMO) 
accumulates at the primary cilium and activates gli family zinc finger 2 (Gli2), which in turn 
regulates gli family zinc finger 1 (Gli1).  Gli1 amplifies hedgehog transcriptional activity.  When 
inactive, suppressor of fused homolog (SUFU) binds to GLI family proteins and represses 
transcriptional activity (Bangs and Anderson 2017) (Bangs and Anderson, 2017). 
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Role of primary cilia in Basal Cell Carcinoma 
 Basal cell carcinoma (BCC) represents the disease state in which the role of primary cilia 
is best understood.  BCC arises in proliferative keratinocytes in the lowest layer of the epidermis.  
In normal physiology, these keratinocytes divide, migrate upwards, and differentiate forming 
additional layers of the epidermis.  UV induced mutations in hedgehog signaling pathway proteins 
drive BCC increasing basal keratinocyte proliferation and inhibiting differentiation.  Bi-allelic loss-
of-function mutations have been identified in PTCH1 and PTCH2, as well as in the hedgehog 
pathway inhibitor, SUFU.  Similarly, mono-allelic activating mutations have been identified in 
SMO.  Constitutive activation or loss of inhibition of downstream signaling via SMO result in 
uncontrolled proliferation that lead to keratinocyte lesions in the epidermis.  Fortunately, BCC is 
not invasive and can often be treated with surgical resection.  In more advanced cases where are 
larger area of skin is impacted, vismodegib and sonidegib, which antagonize SMO, are extremely 
effective.  Although BCC represents a disease state with selection for primary cilia expression, 
primary cilia tend to be lost in cancers arising in other cell types.  Loss of primary cilia has similarly 
been reported in a variety of cancers including pancreatic cancer, renal cell carcinoma, breast 
cancer, cholangiocarcinoma, as well as in melanoma (Choudhury et al. 2020) (Choudhury et al., 
2020). 
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Part 3: Primary Cilia Expression in Nevi and Melanoma. 
In 2011, Kim and colleagues stained paraffin embedded tissue sections of human nevi 
and melanomas in various stages of progression.  They found that melanoma in situ, invasive 
melanoma, and metastatic melanoma were all characterized by loss of primary cilia.  Interestingly, 
nevi retain primary cilia expression, suggesting that expression of this organelle may serve as an 
effective marker to differentiate cases of benign growth-arrested nevi from melanoma.  Because 
primary cilia are naturally disassembled and resorbed during the interphase of cell division, the 
authors asked whether the lack of cilia in melanoma was simply due to the increase in proliferative 
rate of malignant cells.  By co-staining for Ki-67, a cell cycle protein that is expressed in all stages 
of the cell cycle except for G0 (van Dierendonck et al., 1989), they showed that many Ki-67 
negative cells also lacked primary cilia.  This finding suggested that primary cilia expression was 
selected against independently of the proliferative state of melanoma cells (Kim et al. 2011) (Kim 
et al., 2011).   
In 2016, Lang and colleagues confirmed this finding and expanded the role of primary cilia 
staining in the histopathological classification of melanocytic lesions.  They specifically asked 
whether primary cilia expression could differentiate histologically ambiguous atypical dysplastic 
nevi from melanoma.  To do this, they stained formalin fixed tissue sections of human melanocytic 
lesions for acetylated alpha tubulin, which marks the modified tubulins of the ciliary axoneme.  
Gamma tubulin was used to stain the centrosome, indicating the presence and absence of the 
elongated primary cilia.  In addition, the authors co-stained sections with SOX10 to identify nevus 
or melanoma cells of melanocytic origin.  Primary cilia were counted as individual sets of gamma-
tubulin stained centrosomes with an elongated alpha tubulin stained structure.  A primary cilium 
index was then generated for each lesion by dividing the number of SOX10 positive cells with 
primary cilia by the number of total SOX10 positive cells in the tissue section.  They found that, 
while primary cilia staining can be mosaic in atypical dysplastic nevi, the gradient of primary cilia 
expression decreases as the severity of dysplasia in the nevi increases (Lang et al. 2016) (Lang 
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et al., 2016).  This finding strongly suggests that primary cilia expression changes with 
progression from benign melanocytic lesion to melanoma and that it can serve as a useful 
biomarker for differentiating melanocytic lesions with atypical or complex histology. 
 
 
 
 
 
Part 4. Transcriptional profiling of primary cilia-associated genes in nevi and melanoma.   
To better understand the mechanisms underlying primary cilia loss in progression to 
melanoma, we investigated the transcriptional profile of primary cilia-associated genes in nevi 
and melanoma.  We hypothesized that loss of the primary cilium organelle should be preceded 
or accompanied by transcriptional changes in genes encoding primary cilia proteins.  Specifically, 
we thought that genes encoding structural proteins of primary cilia would be downregulated during 
progression to melanoma.  To test this hypothesis, we analyzed transcriptomic data from 20 FFPE 
cases of human nevi with adjacent melanoma.  This cohort comprised 17 nevi, 20 melanomas, 
and 5 intermediate lesions with complex histology that pathologists could not decisively call nevus 
or melanoma.  We next obtained an annotated list of 318 genes thought to be associated with 
primary cilia from the Reiter Lab UCSF, which specializes in primary cilia biology.  This gene list 
derived from an analysis of primary cilia literature and encompassed genes thought to contribute 
to primary cilia structure, signaling molecules that co-localize with primary cilia, as well as genes 
that are thought to negative regulate primary cilia expression.        
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Figure 4.1: Differentially expressed primary cilia-associated gene expression in nevi and 
melanoma. 
Heatmap of differentially expressed primary cilia-associated gene expression in matched 
adjacent nevi (n = 17), melanoma (n = 20), and intermediate lesions (n = 5). 
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Figure 4.2: Nevus-enriched primary cilia gene expression distinguishes nevi from 
melanoma. 
Heatmap nevus-enriched primary cilia-associated gene expression in matched adjacent nevi (n 
= 17), melanoma (n = 20), and intermediate lesions (n = 5). 
 
 
 
 
I preformed differential expression analysis on the module of primary cilia-associated genes to 
determine which of the genes were differentially expressed between nevi and adjacent 
melanomas.  Using DESeq2, I determined that 142 of the 318 cilia genes were differentially 
JJS18_Nev
JJS17_IntM
alig
JJS1_M
el4.T4.
T21_M
el.T1.
JJS10_M
el.T2.
JJS1_M
el3.T4.
JJS21_M
el.T2.
JJS16_M
el.T1.
JJS3_M
el1.T1.
JJS3_M
el2.T1.
JJS22_M
el.T1.
T21_IntM
alig
JJS27_M
el.T1.
JJS28_M
el.T2.
JJS25_M
el.T2.
JJS5_M
el.T1.
JJS19_M
el.T2.
JJS12_M
el.T2.
JJS26_M
el.T1.
JJS18_M
el.T2.
JJS23_M
el.T1.
JJS20_M
el.T2.
JJS14_Nev
JJS14_M
el.T3.
JJS23_Nev
JJS13_IntBenign1
JJS13_IntBenign2
JJS27_Nev
JJS25_Nev
JJS13_IntM
alig
JJS5_Nev
JJS17_Nev
JJS26_Nev
JJS10_Nev
JJS3_Nev
JJS21_Nev
JJS28_Nev
JJS16_Nev
JJS22_Nev
JJS20_Nev
JJS19_Nev
JJS12_Nev
DRD2
SYNE1
DNALI1
ZNF423
KIF26A
PCDH15
DRD1
GLI2
GLI1
CCDC39
IFT74
NEK1
SPATA7
WDR78
ALMS1
BBS9
NT5C2
RFX3
OCRL
TTBK2
FEZ1
LCA5
MNS1
BBS10
IFT52
IFT46
ARL3
DPYSL2
TMEM216
PACRG
LRRC6
NRXN1
TEKT2
IFT122
BBS1
CLUAP1
NPHP1
TCTN1
TTC12
DNAH6
INTU
SPEF2
MKS1
PKD1
IFT140
KIF3A
IFT172
SMO
DYNC2H1
TTC21B
CC2D2A
IFT88
NIN
CRYL1
MAL
HYDIN
SUFU
CEP89
KIF27
NPHP3
BBS2
INVS
PRICKLE2
SPAG6
TTC29
−4
−2
0
2
4
 77 
expressed between the nevus and melanoma samples.  I then performed hierarchical clustering 
using the hclust algorithm as part of the pheatmap R package and plotted the expression of the 
differentially expressed genes as a heatmap (Figure 4.1).  Clustering the transcriptomic profiles 
of primary cilia-associated genes by sample revealed a set of genes enriched in the nevi and 
downregulated in adjacent melanoma, as well as a set of genes enriched in the melanomas and 
downregulated in the adjacent nevi.  The dendrograms show that the majority of the melanoma 
samples cluster together and that the majority of nevus samples cluster more closely together 
than they do with the majority of melanomas.  Surprisingly, there is a set of 5 melanomas that 
cluster in their own node, more closely to the nevi than to the other melanomas.  Furthermore, 4 
of the 5 intermediate lesions (T21_IntMalig, JJS13_IntMalig, JJS13_IntBenign1, and 
JJS13_IntBenign2) clustered more closely with the nevi than the melanoma, while one 
(T21_IntMalig) clustered more closely with the melanomas. 
 To determine if the clustering could be further refined, I performed hierarchical clustering 
using the subset of genes that were shown to be differentially expressed and upregulated in nevi 
in comparison to adjacent melanoma (Figure 4.2).  I found that this gene set improved the 
clustering and that the five melanomas that previously clustered more closely with the nevi now 
clustered more closely with the other melanomas.  It should be noted that this re-cluster caused 
nevus samples JJS18_Nev to become an outlier given that its general gene expression was 
greater than that of the other samples.  However, the pattern of expression is more similar to that 
of the nevi than the melanomas.  Notably, the intermediate lesion T21_Intmalig now clusters more 
closely with the melanomas, while the JJS13_IntMalig and JJS13_IntBenign samples continue to 
cluster more closely with the nevi.  Re-assessment of the JJS13 samples shows that the majority 
of cells in each of the samples still express primary cilia and therefore it is not surprising that the 
cluster more closely with cilia positive nevi.  Finally, the JJS14_Nev and JJS14_Mel cases 
continue to cluster more closely with the nevi, although clearly as their own subset.  Further 
assessment of these lesions need to be performed to determine why that might be the case. 
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 Of the primary cilia-associated genes enriched in nevi, we expected to find genes 
associated with primary cilia construction.  Several genes that contribute to primary cilia structure 
were indeed upregulated in nevi including intraflagellar transport 88 (IFT88), kinesin-like protein 
3A (KIF3A), and centrosomal protein 89 (CEP89).  In 1993, scientists discovered that loss of 
IFT88 in chlamydomonas leads to loss of flagella.  Similarly, mice lacking IFT88 homolog Tg737 
have deformed primary cilia in their kidneys and have polycystic kidney disease (Pazour et al. 
2000) (Pazour et al., 2000).  KIF3A has been shown to be necessary for extending microtubules 
that comprise primary cilia, (Arnaiz et al. 2009 (Arnaiz et al., 2009), Avidor-Reiss et al. 2004 
(Avidor-Reiss et al.), Liu et al. 2007, (Liu et al., 2007) Pazour et al. 2005 (Pazour et al., 2005), 
Wigge et al. 1998) (Wigge et al., 1998).  CEP89 is a centrosomal protein whose loss has similarly 
been associated with loss of primary cilia (Andersen et al. 2003) (Andersen et al., 2003), Nogales-
Cadenas et al. 2009) (Nogales-Cadenas et al., 2009).  Additionally, SYNE1, a gene that is also 
essential for primary cilia is shown to be upregulated in nevi (Liu et al., 2007) (Stubbs et al., 2008).   
 Besides genes associated with primary cilia structural elements, hedgehog pathway 
signaling molecules that typically associate with primary cilia are upregulated in nevi.  These 
include SMO, which localizes to the cilia membrane when sonic hedgehog (SHH) is bound to the 
receptor PTCH1.  Similarly, GLI2, which localizes together with other hedgehog proteins in the 
cilium tip (Blacque et al., 2005) is also upregulated.  In addition, GLI1, which is not found in the 
cilium, but interacts with GLI2 and amplifies hedgehog pathway signaling is also upregulated.  
Interestingly, SUFU, which suppresses hedgehog signaling is likewise enriched in nevi in 
comparison to melanoma.  This is likely due to the localization of SUFU together with the GLI 
transcription factors to the ciliary tip (Laurençon et al., 2007), an event that cannot occur in the 
absence of primary cilia expression typically observed in melanoma. 
 Taken together, the enrichment of genes associated with primary cilia structure and genes 
that encode signaling molecules that localize to the cilium in nevi but not in melanoma suggests 
that there are transcriptional changes that underlie the loss of primary cilia during progression to 
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melanoma.  Indeed, with few exceptions, the expression of primary cilia genes enriched in nevi in 
comparison to adjacent melanoma effectively clusters the nevus and melanoma samples of this 
cohort.  An expanded cohort is required to validate whether this method of clustering is generally 
applicable to nevi and melanoma.  Furthermore, this work suggests that the visible loss of primary 
cilia, as assessed by cilia protein staining, can be attributed to change in transcriptional program 
within melanoma cells that actively suppresses primary cilia expression. 
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Chapter 5: Discussion  
 
Cell-intrinsic factors contribute to the growth-arrested state of melanocytic nevi. 
Taken together, the research compiled in this dissertation demonstrates that many cell-
intrinsic factors contribute to establishing and maintaining the growth-arrested state of 
melanocytic nevi.     
 
Cyclin dependent kinase inhibitors contribute to nevus growth arrest and their loss 
permits progression to melanoma. 
We have shown that BRAFV600E signaling directly induces transcriptomic changes in 
human melanocytes, including the upregulation of cyclin dependent kinase inhibitors including 
p15INK4B and p16INK4A.  Although p15INK4B and p16INK4A play variable roles in nevus development, 
the upregulation of these inhibitors blocks cell cycle progression and their subsequent genetic 
loss provides a route to the malignant transformation of nevi.  Furthermore, loss of p16INK4A proves 
necessary for inducing invasive and metastatic behaviors in melanoma cells. 
 
microRNAs establish and maintain the transcriptome of growth-arrested nevi. 
We further demonstrate that microRNAs contribute to establishing and maintaining the 
growth arrest state of nevi.  Specifically, MIR211-5p and MIR328-3p regulate networks of target 
genes in melanocytes that converge on AURKB and ultimately inhibit cell cycle progression.  The 
subsequent downregulation of MIR211-5p and MIR328-3p relieves that repression and provides 
additional transcriptomic remodeling that permits malignant transformation.     
 
Primary Cilia formation supports the nevus state. 
Our research also suggests that formation of the primary cilia organelle through the 
transcription of primary cilia- related genes contributes to growth-arrest in nevi.  
Immunohistochemistry clearly shows that melanoma cells express primary cilia at far lower levels 
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than nevi.  By examining transcriptomic data from matched human nevus and adjacent melanoma 
samples, we observe distinct transcriptional signatures for nevi and melanoma with regard to cilia-
related genes. 
 
Future directions: 
While this work highlights several cell-intrinsic factors that contribute to the formation and 
maintenance of human BRAFV600E-induced melanocytic nevi, the full complexity of nevi remains 
elusive.  Fully dissecting the cell-intrinsic changes induced by mutant BRAFV600E expression in 
human melanocytes, and determining the convergence points of these changes, appears 
fundamental to understanding growth-arrest in nevi.  Further research examining the plasticity of 
the nevus transcriptome that nevus eruption and nevus recurrence, while maintaining the 
durability of long-term growth arrest should be prioritized.  Moreover, determining which factors 
critical to nevus formation are necessary to restrain melanocytic nevi from transforming to 
melanoma will provide therapeutic opportunities to improve our treatment of this disease. 
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Materials and Methods 
 
Methods for McNeal et al. 2015: 
Isolation of Melanocytes from Human Nevi 
Benign human melanocytic nevi were excised from patient donors seen in the Dermatology clinic 
at the Hospital of the University of Pennsylvania according to an IRB approved protocol.  A portion 
of each specimen was processed for routine histological examination to confirm the clinical 
diagnosis of benign nevus.  The tissue samples were microdissected to isolate nevus from 
surrounding normal tissue.  Nevus tissue was then mechanically separated into fine pieces, and 
enzymatically dissociated in a mixture of dispase and collagenase for 2 hours.  The resulting 
supernatant was spun at 218g for 5 minutes to pellet the extracted cells, which were subsequently 
resuspended in melanocyte Medium 254 (Invitrogen). The cells were plated onto 6-cm collagen-
coated tissue culture plates (BD Falcon). Melanocytes were further isolated from contaminating 
fibroblasts by selective trypsinization and 4 day exposure to 100 μg/mL G418. 
 
Melanocyte Culture 
 Primary melanocytes were extracted from fresh discarded surgical human foreskin specimens 
as described previously (28) with some modifications detailed as follows. After overnight 
incubation in Dispase, the epidermis was separated from the dermis and treated with trypsin for 
10 minutes.  Cells were pelleted and plated on selective MC Medium 254 (Invitrogen) with Human 
Melanocyte Growth Supplement, and 1% penicillin and streptomycin. TGFb-1 was purchased 
from R&D Systems and used at a concentration of 100 pM. Doxycycline (hyclate) hydrochloride 
was purchased from Sigma, dissolved in sterile, deionized water, and used at a concentration of 
0.25µg/mL.  SB-431542 was purchased from EMD Millipore, dissolved in DMSO, and used at a 
concentration of 50µM. 
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Immunoblot Analyses and Antibodies 
Adherent cells were washed once with DPBS and lysed with 1% NP-40 buffer (150 mM NaCl, 50 
mM Tris, pH 7.5, 1 mM EDTA, and 1% NP-40) containing 1X protease inhibitors (Roche) and 1X 
phosphatase inhibitors (Roche).  Lysates were quantified (Bradford assay), normalized, reduced, 
denatured (95 ˚C) and resolved by SDS gel electrophoresis on 4-15% Tris/Glycine gels (Bio-
Rad).  Resolved protein was transferred to PVDF membranes (Millipore) using a Semi-Dry 
Transfer Cell (Bio-Rad), blocked in 5% dry milk in TBS-T and probed with primary antibodies 
recognizing BRAF (Abcam, ab33899, 1:500), BRAF-V600E (Spring Bioscience, VE1, 1:500), p15 
(Abcam, ab 53034, 1:500), p16 (BD Pharmingen, #551153, 1:500), and β-Actin (Cell Signaling 
Technology, #3700, 1:4000).  After incubation with the appropriate secondary antibody, proteins 
were detected using either Luminata Crescendo Western HRP Substrate (Millipore) or ECL 
Western Blotting Analysis System (GE Healthcare). 
 
Immunohistochemistry  
Formalin fixed paraffin embedded (FFPE) human skin tissue sections from patients with benign 
nevus and melanoma, or human xenograft tissues were screened for p15 protein expression 
using peroxidase/DAB (diaminobenzidine)-complex method (EXPOSE biotin free detection kit, 
Abcam, Cambridge, MA).  Tissue sections were deparaffinized and rehydrated. To retrieve the 
antigens, tissue sections were microwaved in 10mM Citrate buffer pH 6.0.  To quench 
endogenous peroxidase, tissues were incubated in 3% H2O2 . Tissues were then incubated with 
primary antibody to p15 (1:200; Abcam, Cambridge, MA) for three hours at room temperature. 
The secondary antibody, goat anti-rabbit HRP conjugated, was supplied with the kit and incubated 
18 min at room temperature. Following multiple washes in TBS, the antigen-antibody complex 
was visualized with 3.3% DAB-solution. The tissues were counterstained with hematoxilin, 
dehydrated and a coverslip was applied. 
 
 
 84 
Quantification of Immunohistochemistry Staining 
Tissue sections from human nevi, melanomas, and melanomas arising in continuity with existing 
nevi were stained for p15 or p16 expression using methods described in the previous 
immunohistochemistry section.  10X photomicrograph images of representative tissue sections 
were taken using the Zeiss microscope.  Tiff files of the images were saved and transferred to 
Adobe Photoshop where pixels corresponding to p15 or p16 IHC staining were selected using the 
color selection tool.  Images corresponding to the single specific color were then  analyzed using 
FIJI (Image J) to determine the number of pixels in each sample.  The number of pixels 
representing the total staining, including the DAPI counterstain, was also obtained so that the 
levels of p15 and p16 expression could be normalized to the total amount of label in each section.  
Final ratios of p15 and p16 expression were calculated by dividing the number of p15 or p16 pixels 
by the total pixels in each section.      
 
Generation of Lentiviral Vectors 
The following lentiviral plasmids were used to express the corresponding human genes: diBRAF, 
p15, p16, CDK4(R24C), dominant-negative p53(R248W), hTERT, and luciferase.  The human 
BRAF (V600E) gene was inserted immediately after the TetO operator in a modified version of 
the doxycycline-inducible lentiviral pTRIPZ vector (Thermo Scientific), in which the shRNA hairpin 
sequences were deleted.    Human p15 (Addgene 16454), CDK4(R24C), p53(R248W), and 
hTERT (28) were cloned into the pRRL lentivector (40).  Human p16 was expressed using 
Addgene plasmid #22263 (Eric Campeau). shRNAs were expressed from pLKO.1 and are 
available through OpenBiosystems.  The nucleotide sequences of the specific hairpin sequences 
used are available upon request. 
 
Quantitative RT/PCR 
mRNA was extracted from melanocytes according to the RNeasy Mini Kit  protocol (Qiagen), and 
reverse transcribed to cDNA using the High Capacity RNA-to cDNA kit (Applied 
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Biosystems).  Quantitative PCR of the resulting cDNA was carried out using Power SYBR Green 
Master Mix (Applied Biosystems) and gene-specific primers, in triplicate, on a ViiA 7 Real-Time 
PCR System (Life Technologies). The following primers were used for detection; CDK2 forward: 
5’-CAG GAT GTG ACC AAG CCA GT-3’; CDK2 reverse: 5’-GGC TGG CCA AGA CTA GAA GG-
3’; CDK4 forward: 5’- GTG CAG TCG GTG GTA CCT GA-3’; CDK4 reverse: 5’- AAG GCA AAG 
ATT GCC CTC TCA-3’; CDK6 forward: 5’ – ACA GAG CAC CCG AAG TCT TG – 3’; CDK6 
reverse: 5’-CTG GGA GTC CAA TCA CGT CC-3’; p14ARF forward: 5’- ACG GGT CGG GTG 
AGA GTG -3’; p14ARF reverse: 5’- GTG GCC CTC GTG CTG ATG -3’; p15 forward: 5’- CAC 
CCC CAC CCA CCT AAT TC-3’; p15 reverse: 5’-TGA GTG TCG AGG GCC AGA TA-3’; p16 
forward: 5’-GCC CAA CGC ACC GAA TAG-3’; p16 reverse: 5’- ACG GGT CGG GTG AGA GTG 
-3’; p18 forward: 5’- GTG GGG CAT CGG AAC CAT AA-3’; p18 reverse: 5’- AAA GTA GAG GCA 
ACG TGG GG-3’; p21 forward: 5’- GAT GTA GAG CGG GCC TTT GA-3’; p18 reverse: 5’- AAA 
GTA GAG GCA ACG TGG  GG -3’. Relative expression was determined using the 2-[delta][delta] 
Ct method followed by normalization to the wild-type melanocyte transcript levels.  
 
Growth Curves 
 Cells were seeded into 6-well plates at a density of  2.0 x 105 or 2.5 x 105 cells per well.  At 
regular intervals, cells were trypsinized, resuspended, and  manually counted on Kova Glasstic 
Slide 10 (Hycor).   Cells were subsequently spun down and re-seeded into 6-well plates at equal 
densities. 
 
Sanger Sequencing 
 mRNA was isolated from nevus melanocytes using the RNeasy kit and reverse transcribed to 
cDNA. Sanger sequencing was conducted by the University of Pennsylvania DNA Sequencing 
facility.  Samples submitted contained 60 ng DNA, and 3.2 pmoles each of forward and reverse 
primers in a volume of 9 μL.  The sequencing primers used were ordered from Integrated DNA 
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Technologies and are as follows; BRAF forward: 5’- GCA CGA CAG ACT GCA CAG GG -3’; 
BRAF reverse: 5’- AGC GGG CCA GCA GCT CAA TAG -3’. 
 
Preparation of 3-D Organotypic Skin Cultures 
 Organotypic skin grafts containing MCs were established using modifications to previously 
detailed methods (10, 28).  The Keratinocyte Growth Media (KGM) used for keratinocyte-only skin 
grafts was replaced with Melanocyte Xenograft Seeding Media (MXSM).  MXSM is a 1:1 mixture 
of KGM and Keratinocyte Media 50/50 (Gibco) containing 2% FBS, 1.2 mM calcium chloride, 100 
nM Et-3 (endothelin 3), 10 ng/mL rhSCF (recombinant human stem cell factor), and 4.5 ng/mL r-
basic FGF (recombinant basic fibroblast growth factor). 1.5 x 105 melanocytes and 5.0 x 105 
keratinocytes were suspended in 80 μL MXSM, seeded onto the dermis, and incubated at 37 ˚C 
for 4 days at the air-liquid interface. 
 
Mouse Xenografting 
Organotypic skin tisssues were grafted onto 5-7 week old female ICR Scid mice (Taconic) 
according to an IACUC-approved protocol at the University of Pennsylvania.  Mice were 
anesthetized in an isoflurane chamber.  Murine skin was removed from the upper dorsal region 
of the mouse. Reconstituted human skin was reduced to a uniform 11 x 11 mm square and grafted 
onto the back of the mouse with individual interrupted 6-0 nylon sutures. Mice were dressed with 
Bactroban ointment, Adaptic, Telfa pad and Coban wrap.  Dressings were removed 2 weeks after 
grafting. 
 
Viral Transfection and Transduction 
  Viral transductions were performed as described previously (10, 27, 28). HEK293T cells were 
cultured to 40% confluency and incubated in DMEM supplemented with 5% FBS and 1% antibiotic 
and antimycotic in 6-well plates. For each well, 1.22 µg lentiviral vector was mixed with viral 
packaging plasmids pCMVΔR8.91 (0.915 µg) and pUC-MDG (0.305 µg). This plasmid solution 
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and 7.2 µl of Fugene 6 Transfection Reagent (Promega) were added to 96 µl of supplement-free 
DMEM. The resulting mixture was incubated at room temperature for 15 minutes and then added 
into the HEK293T culture media. At 16 hours post-transfection, 10 mM sodium butyrate was 
added onto the cells. At 24 hours, the culture media was replaced and the cells were incubated 
at 32°C. At 45 hours, viral supernatant was collected by filtering the media through a .45 µm 
syringe filter (Argos). Melanocytes seeded at 2.5 x 106 cells per well were incubated in viral 
supernatant in the presence of 5 µg mL-1 polybrene and centrifuged at 300 x g for 60 minutes at 
room temperature. After incubating the transduced melanocytes for 15 minutes at 37ºC, viral 
supernatant was removed and replaced with growth media.  
 
CRISPR-Cas9 Cloning and Transduction 
 Guide RNAs were designed using software tools developed by the Zhang Lab and provided on 
the website http://www.genome-engineering.org/ (Hsu et al., 2013).  Guide RNAs were 
subsequently cloned into lentiCRISPRv2 (Addgene # 52961) according to the accompanying 
protocol (Sanjana et al., 2014 and Sanjana et al., 2014).  Guide RNA sequences are as follows: 
lentiCRISPR GFP 5’ GAA GTT CGA GGG CGA CAC CC 3’; lentiCRISPR p15.2 5’ CCC GAA 
ACG GTT GAC TCC GT 3’.  LentiCRSIPR transductions in human melanocytes were conducted 
as previously described for the other lentiviral constructs used in this study.  
  
Statistics 
 Mean values were compared using an unpaired Student’s two-tailed T-Test. 
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Zeng et al. 2018 Methods 
 
Analysis of clinical specimens and sequence 
Histopathologic Assessment 
Clinical specimens were collected and analyzed in compliance with the UCSF Human Research 
Protection Program (11-07951). Two cohorts of transitional lesions were analyzed in this study. 
A transitional lesion is a lesion with two or more histopathologically distinct areas – for example, 
in Figure S5A, we show three transitional lesions - one with a portion of benign nevus and a 
portion of invasive melanoma; one with a portion of MIS and a portion of melanoma; and one with 
a portion of MIS and a portion of nevus. By analyzing transitional lesions we could perform inter- 
and intra- tumoral comparisons in order to identify the stage at which CDKN2A loss occurred both 
within individual tumors and across many tumors.  
The first cohort of transitional lesions comprised 82 cases for which we performed DNA 
sequencing to determine the timing of CDKN2A somatic alterations during melanoma 
progression. This cohort spanned a broad spectrum of histopathologically distinct areas, including 
31 nevus areas, 18 melanoma in situ areas, 23 thin invasive melanoma areas (stage T1), and 32 
thick invasive melanoma areas (stage T2+). In a subset of 20 of these transitional lesions with 
sufficient material to isolate both DNA and RNA, we also performed RNA-sequencing to identify 
the relationship between CDKN2A loss and p16INK4A or BRN2 expression. 
The second cohort of transitional lesions was comprised of 23 cases for which we utilized Melan-
A, BRN2, Ki67 and p16INK4A immunostaining in order to confirm the timing of p16INK4A loss at the 
protein level and its relationship to other BRN2 and Ki67. This cohort had a more focused 
spectrum of histopathologic areas, encompassing nevi associated with melanoma in situ or 
melanoma in situ associated with invasive melanoma. 
Cases from both cohorts were retrieved from the UCSF Dermatopathology archive as formalin-
fixed paraffin-embedded tissue blocks. Sequencing was performed by the UCSF Clinical Cancer 
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Genomics Laboratory and protein staining by the UCSF Dermatopathology and Oral Pathology 
Service. 
Histopathologically distinct areas associated with each transitional lesion were independently 
evaluated by a panel of 3-8 dermatopathologists for staging and/or immunostaining interpretation. 
Transitional lesions include nevus, melanoma in situ, invasive thin melanoma (T1 melanoma) and 
invasive thick melanoma (T2 melanoma or higher).  For genomic analysis, distinct areas were 
manually microdissected with a scalpel and dissection scope from a series of 10-20um unstained 
sections following the guidance of a pathologist.   
 
Genomic Analysis 
Genomic DNA was sequenced as previously described (Shain et. al. NEJM 2015 4). Briefly, 25-
250ng of genomic DNA was prepared for sequencing using KAPA Biosystems Illumina compatible 
library preparation kit (KAPA Hyper Prep Kit, Cat# KK8504). Target enrichment was performed 
using a custom gene panel of approximately 500 genes (SeqCap EZdeveloper library 24 
reactions, Ref #: 06471706001, gmi.ucsf.edu/testing/). 100bp paired-end sequencing was 
performed on an Illumina HiSeq 2500 instrument. For clinical samples, CDKN2A gene status was 
analyzed in this study. Read alignment, mutational analysis, and copy number analysis was 
performed as previously described4,57. Thirty-seven transitional lesions were previously 
sequenced and reanalyzed here 4. 
For comparison of WM793 and 1205Lu cell lines, after sequencing as described above, their 
genomic landscapes were compared, as previously described 4, to delineate the shared (trunk) 
and private (branch) mutations in each cell line (see Figure 4C). There was no source of normal 
tissue associated with these cell lines, and therefore somatic point mutations were inferred by 
subtracting known SNPs (1K Genome Project) from variants. It is likely that a small number of 
private, germline SNPs are present in the trunk of the phylogenetic tree, however, this did not 
hinder the goal of this analysis, which was to identify differences between the two cell lines. 
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Transcriptomic analysis 
Matched RNA-sequencing was performed on a subset of 20 transitional lesions. For this subset 
of cases, every other unstained section was microdissected and used instead for RNA isolation 
(Ambion 1975). 100ng of total RNA was prepared for sequencing using KAPA stranded RNA-Seq 
Library Preparation Kit (KR0934). This kit uses random priming for cDNA synthesis, and thus 
target enrichment was performed using xGen Lockdown Reagents (Cat# 1072281) and 
Nimblegen Capture Baits (Roche, customized), thereby depleting ribosomal RNA prior to 
sequencing. 100bp paired-end sequencing was performed on an Illumina HiSeq 2500 instrument. 
P16INK4A and BRN2 gene status were analyzed in this study. Sequencing reads were aligned 
using STAR 58  and transcript abundance was estimated using RSEM 59. 
For melanocytes, RNA sequencing was performed on 3 sets of wild-type and CDKN2Aex2::CMV-
EGFP melanocytes preparations. Library construction was performed using TruSeq Stranded 
mRNA LT (Illumina) followed by single end 75-bp sequencing on the NextSeq 500 (Illumina). QC 
was performed using FastQC followed by trimming using Trimmomatic60. Sequencing reads were 
aligned using Tophat with differential analysis performed using CuffDiff 61. 
 
Cell culture and analysis 
Melanoma lines 
The WM793 and 1205Lu melanoma lines were gifted by the Herlyn lab (Herlyn et al Cancer 
Research 1985)41, and grown in DMEM H-16 supplemented with 10% FBS (Corning, 35-010-CV), 
0.1mg/mL Pen-Strep, and 0.002mg/mL L-Glutamine at 37°C with 5% CO2.  
 
Primary melanocytes 
Foreskins were provided by Dr. Thea Mauro in accordance with UCSF Human Research 
Protection Program protocol. After PBS washing, the skin was cut into 1cmx1cm squares and 
cleared of fat prior to incubation with Dispase for 24hours at 4°C with the epidermis side facing 
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upwards. After washing, the epidermis was isolated, sectioned into small pieces, and trypsinized 
at 37°C for 5 minutes. After quenching and low-speed centrifugation, cell pellets were plated in 
NHM media (Medium 254 (ThermoFisher M254500) supplemented with HMGS (ThermoFisher 
S0025) and Pen-Strep) and incubated at 37°C overnight. Fresh media containing G418 (1ug/ml) 
was added 24 hours later until a pure NHM population was observed. Once established in culture, 
NHMs were verified as pigmented, possessing melanocyte morphology, and expressing Sox10 
and Melan-A as follows: cells were washed with PBST (PBS with 0.05% TritonX), blocked with 
PBST with 3%BSA and 0.01%Donkey serum for an hour, incubated with primary antibody (Table 
S2) in blocking buffer overnight at 4°C, washed, incubated with secondary antibody (anti-rabbit-
Cy5, anti-mouse 488 and anti-goat 594 (Life Technologies)) for 2 hours, washed with DAPI-
containing PBST, and imaged. After verification, NHMs were maintained in NHM media. Medium 
was refreshed twice a week and cells were passaged upon reaching 80% confluence with 0.05% 
Trypsin quenched 1ml 0.5mg/ml serpin trypsin inhibitor (Life technologies 17075029).  
 
Lentivirus transduction 
293T cells were co-transfected with 3rd generation lentivirus packaging vectors and expression 
construct (pSico-mcherry, pSico-shINK4A-mCherry, pHIV-EF1a-IRES-ZsGreen, pHIV-EF1a-
IRES-INK4A-ZsGreen or pHIV-EF1a-IRES-ARF-ZsGreen) using jetPRIME transfection reagent 
(Polyplus 114-15). Virus was harvested 72 hours post transfection, filtered through 0.45um filter 
and 10ug/ml of Polybrene (SIGMA H9268) was added prior to plating. Media was switched to 
standard culture media either 24 hours (cell lines) or 6 hours (NHM) post infection. 72 hours post 
infection the cells were trypsinized, washed in PBS, filtered and sorted for mCherry, mOrange2 
or ZsGreen positive cells. 
 
Transfection 
NHMs were transfected using the Neon Electroporation system (ThermoFisher), as described in 
the manufacture’s protocol. Briefly, NHMs were trypsinized, washed, and resuspended in R buffer 
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at a final concentration of 2.0 × 107 cells/mL. Cells were mixed with either 150pmol siRNA, 1ug 
expression or reporter plasmid or CRISPR/Cas9-HDR reagents (see NHM engineering) and 
electroporated with two 20ms 1500V pulses in a 10uL Neon transfection tip (ThermoFisher 
MPK1096), then plated into 500uL pre-warmed media in a 24-well tissue culture treated plate.  
Cell lines were transfected using either jetPRIME transfection reagent (Polyplus 114-15) for 
plasmid or Lipofectamine RNAiMax (ThermoFisher 13778150) for siRNA. The concentration of 
siRNA, plasmid and transfection reagent followed the manufacture’s protocol. 
 
Flow cytometric analysis 
Primary melanocytes, 1205Lu and WM796 melanoma cells were either CRISPR engineered to 
be EGFP positive, or transduced to be mCherry, mOrange2 or ZsGreen positive. Fluorescent 
protein expressing cells were sorted out for pure populations. The cells were trypsinized, 
centrifuged and resuspended in PBS, following which they were analyzed and sorted on the 
FACSAria III (BD biosciences) on the FITC channel (ZsGreen+ and EGFP+ cells) or PE channel 
(mOrange2+ and mCherry+ cells). Further analysis and quantification was performed using FlowJo 
(Treestar) 
 
Holographic imaging and microscopy 
Holographic imaging was conducted as previously described 34. Briefly, imaging was conducted 
with a HoloMonitor M4 imaging cytometer with high precision automated stage (Phase 
Holographic Imaging, Lund, Sweden) installed in a standard tissue culture incubator. Cells were 
plated in 6-well standard tissue culture plates, plated at 10,000 – 100,000 cells per well depending 
on cell type and experiment and covered with a Hololid (PHI). For motility analyses, holograms 
were generated every hour for indicated time and analyzed using the Hstudio software package 
(PHI). For growth arrest analyses, cells were classified based upon quantitative optical metrics 
as previously described 34, where cells were defined as growth arrested if they stopped dividing 
while adopting a morphology indistinguishable from NHMs treated with CDK4/6 inhibitor62.  
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Fluorescent images were captured with an EVOS FL inverted microscope (ThermoFisher), 
colored images were captured with a Lieca Dmi1 light microscope, and high quality scans of 
clinical specimens were scanned with a ScanScope XT scanner (Aperio).  
 
Invasion analyses 
In vitro invasion assays were conducted using transwell cassettes coated with high-density 
basement membrane extract as described in manufacture’s protocol (Trevigen, 3483-096-K) 
 
NHM engineering 
Introduction of BRAFV600Epoint mutation 
crRNA (Table S3, IDT) and tracrRNA (IDT 1072533) were resuspended in nuclease-free IDTE 
buffer (IDT 11-01-02-02) and combined for a final concentration of 100μM each and assembled 
into sgRNA via heating at 95ºC for 5min then cooled to room temperature. Cas9:sgRNA RNPs 
were formed by combining 120pmol sgRNA and 100pmol recombinant Cas9 protein (qb3 
Berkeley), heating at 37ºC for 5min then cooling to room temperature. 120pmol of 
crRNA:tracrRNA complexes was mixed with 100pmol BRAF ssOligo HDR template (Table S3), 
then electroporated into low-passage NHMs (passage 2-5 after isolation) as described above. 
sgRNA and ssOligo HDR template, without recombinant Cas9, were transfected for no Cas9 
controls. After electroporation, NHMs were plated directly into media containing 5μM L755507 for 
enhancement of HDR recombination63. After 3 days, genomic DNA was harvested for indel 
analysis via the TIDE approach64. 
 
Introduction of CDKN2A knock-in 
Low-passage NHMs (passage 2-5 after isolation) were electroporated as described above with 
800ng each of pHDR-CDKN2A-Ex2-CMV-EGFP, pEN35-CDKN2A-Ex2-L and pEN35-CDKN2A-
Ex2-R and plated directly into media containing 5μM L755507 for enhancement of HDR 
recombination 63.  pHDR-CDKN2A-Ex2-CMV-EGFP without pEN35 plasmids were transfected as 
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no Cas9 controls. Transfected NHMs were maintained and expanded in normal conditions until 
fluorescent signal was no longer observed in no Cas9 controls (~ 3weeks). EGFP positive and 
EGFP negative cells were then sorted from the Cas9 and no Cas9 populations, respectively to 
generate CDKN2A::EGFP and wild-type sibling NHMs.  
 
Mouse injection and metastasis assay 
All protocols described in this and other sections regarding animal studies were approved by the 
UCSF Institutional Animal Care and Use Committee. Ethical endpoint for tumor transplantation 
experiments was reached when a tumor reached = 2.5 cm in any single dimension. Transduced 
WM793 and 1205Lu cells were sorted and subcutaneously injected (8 × 106 cells) into immuno-
deficient female mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) aged 6~8 weeks by a technician 
blinded to the identity of the cells. Each week the mice were monitored for tumor size using a 
digital caliper and recorded with the guidance of the Helen Diller Comprehensive Cancer Center 
Preclinical Core (UCSF). 5 weeks post injection the lungs were perfused with 4%PFA, and mice 
were humanely sacrificed. A piece of each lobe was harvested for obtaining genomic DNA and 
the remaining lobes were incubated in sucrose overnight to be used for immunofluorescence and 
H&E staining. 
 
Lung metastasis was determined by staining of human nuclei specific primary antibody (HNA 
Table S2). Primary tumor and lung were sectioned on a cryostat and incubated at room 
temperature for 20 minutes. The sections were washed with PBST, blocked with 3%BSA PBST, 
incubated with primary antibody 1:50 in blocking buffer overnight, washed 2 times with PBST, and 
incubated with secondary antibody anti-Cy5/488 (Life Technologies) for 2 hours. After washing, 
the slides were coated with 20ul of mounting media with DAPI (Life Technologies) and HNA 
positive cells were counted by an observer blinded to the identity of each sample.  
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Molecular Biology 
Western blot analysis 
Protein extracts were mixed with NuPAGE LDS Sample Buffer (ThermoFisher NP0007), NuPAGE 
Sample Reducing Agent (ThermoFisher NP0004) and heated for 10min at 70°C. Protein 
(10ug/lane) was resolved on NuPAGE Novex 4-12% or 16% Bis-Tris Protein Gels, 1.0 mm, 15-
well (ThermoFisher NP0323BOX) and transferred using a Mini-Trans-Blot Cell Trans-Blot semi-
Dry transfer cell (BioRad) onto 0.22Um PVDF membranes (ThermoFisher 88520). Membranes 
were blocked with Membrane Blocking Solution (ThermoFisher 000105) for 1 hour at room 
temperature (22°C). The membranes were then incubated overnight at 4°C with primary 
antibodies (Table S2). The membranes were washed with TBS and 0.1% Tween20 (TBST), 
incubated with horseradish peroxidase-conjugated secondary antibody (GE Healthcare NA934) 
1:15000 for 1 hour at room temperature, washed four times with TBST, and visualized with Lumina 
Forte Western HRP substrate (Millipore WBLUF0500).  
 
RT-qPCR 
RNA from cell lines was isolated with TRI reagent according to the manufacturer’s protocol (Sigma 
T9424). RT-qPCR was performed following the instructions for SensiFAST cDNA Synthesis Kit 
and SensiFAST SYBR No-ROX Kit (Bioline BIO-65053 & BIO-98020) with CFX96 Real-Time PCR 
Detection System (BioRad). Relative expression level was calculated using 2−ΔΔCT method. 
RPL90 was used as a housekeeping gene for normalization. The sequences of primers used for 
qPCR analysis are listed in Table S3. 
 
Human genomic DNA qPCR 
Genomic DNA was isolated using ISOLATE II Genomic DNA Kit (Bioline BIO-52067). Quantitative 
PCR was performed to detect human DNA in mouse lung using SensiFAST SYBR No-ROX Kit 
(Bioline BIO-98020) on the CFX96 Real-Time PCR Detection System(BioRad). Standard curves 
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using known concentrations of pure human genomic DNA were generated to calculate absolute 
value. The sequences of primers used for qPCR analysis are listed in Table S3. 
 
Digital droplet qPCR 
FAM- and HEX- tagged probes that specifically bound BRAF V600 and E600 alleles, respectively, 
were designed as non-binding sense strands to the ddOligo HDR template (Table S3). A PCR 
primer was designed to span the probe-binding region.  Probes and primers were synthesized by 
Bio-Rad. PCR reactions were assembled using premixtures of each probe (5μM) and primer 
(18μM), 150ng genomic DNA, FAM and HEX probes and ddPCR Supermix (Bio-Rad) according 
to manufacture’s protocol. Droplet generation with a QX100 Droplet Generator was performed 
according to the manufacturer’s instructions (Bio-Rad), and the reaction was transferred into a 
96-well PCR plate for standard PCR on a C1000 Thermal Cycler (Bio-Rad). The thermal cycling 
program conducted was: step 1, 95 °C 10 min; step 2, 94 °C 30 s; step 3, 50 °C–58 °C or 60 °C 
gradient 1 min; repeat steps 2 and 3 39 times; step 4, 98 °C 10 min. After the PCR was completed, 
the droplets were analyzed using a QX100 Droplet Reader (Bio-Rad).  BRAFV600E mutation 
percentage was calculated based on the copy number of BRAFV600E per ul (x) and the copy 
number of BRAFWT per ul (y) with the formula: percentage of BRAFV600E (%)= X/(X+Y)*100. 
 
Telomere length assay 
The telomere length measurement assay is adapted from the published original method by 
Cawthon (Cawthon et al Nucleic Acids Res 2002; Lin et al Journal of Immunological Methods 
2010)65,66. The telomere thermal cycling profile consists of: 
Cycling for T(telomic) PCR: 96°C for 1 minute; denature at 96°C for 1 second, anneal/extend at 
54°C for 60 seconds, with fluorescence data collection, 30 cycles.  
Cycling for S (single copy gene) PCR: PCR: 96°C for 1 minute; denature at 95°C for 15 seconds, 
anneal at 58°C for 1 second, extend at 72°C for 20 seconds, 8 cycles; followed by denature at 
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96°C for 1 second, anneal at 58°C for 1 second, extend at 72°C for 20 seconds, hold at 83°C for 
5 seconds with data collection, 35 cycles.  
The primers for the telomere PCR are tel1b [5'-CGGTTT(GTTTGG)5GTT-3'], used at a final 
concentration of 100 nM, and tel2b [5'-GGCTTG(CCTTAC)5CCT-3'], used at a final concentration 
of 900 nM. The primers for the single-copy gene (human beta-globin) PCR are hbg1 [5' 
GCTTCTGACACAACTGTGTTCACTAGC-3'], used at a final concentration of 300 nM, and hbg2 
[5'-CACCAACTTCATCCACGTTCACC-3'], used at a final concentration of 700 nM. The final 
reaction mix contains 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 200  M each dNTP; 1% DMSO; 0.4x 
Syber Green I; 22 ng E. coli DNA per reaction; 0.4 Units of Platinum Taq DNA polymerase 
(Invitrogen) per 11 microliter reaction; ~6 ng of genomic DNA. Tubes containing 26, 8.75, 2.9, 
0.97, 0.324 and 0.108ng of a reference DNA (human genomic DNA from buffy coat, Roche 
11691112001) are included in each PCR run so that the quantity of targeted templates in each 
research sample can be determined relative to the reference DNA sample by the standard curve 
method. The same reference DNA is used for all PCR runs. 
To control for inter-assay variability, 8 control DNA samples are included in each run, and the T/S 
ratio is calculated.  If the T/S ratio for duplicates varies by more than 7%, the sample is re-run. 
The average CV for this study was 1.6%. 
 
Plasmid construction 
The lentiviral expression construct pHIV-ZsGreen was a gift from Bryan Welm and Zena Werb 
(Addgene plasmid # 18121) 67. pHIV-mOrange2 was constructed by digesting pHIV-zsgreen with 
Bau151 and inserting the mOrange2 coding sequence.  pHIV-INK4A-zsGreen, pHIV-ARF-
zsGreen, pHIV-ARF-mOrange2, pHIV-INK4A-mOrange2, and pHIV-BRAFV600E-mOrange2 
were all generated by inserting the indicated coding sequence into the EcorI and XbaI sites of the 
indicated parental pHIV constructs. pSicoR-Ef1a-mCh-Puro was a gift from Bruce Conklin 
(Addgene plasmid # 31845, Salomonis, et, al. PNAS 2010). pGL410-BRN2p (BRN2 promoter 
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luciferase reporter) was generated by placing 2kb of sequence upstream of the BRN2 
transcriptional start site into the Bgl2 and Xho1 sites. pHDR-CDKN2A was generated by 
amplifying 2kb left and right arms from human genomic DNA and using Cold Fusion (System Bio) 
to combine with the CMV promoter, EGFP ORF, and an Amp/Ori cassette. For conducting double 
nickase CRISPR-Cas9, we used pEN35, generously provided by Elphege Nora. pEN35 was 
constructed by introducing the (F&E) modification into the sgRNA backbone of px33532,33. All 
constructed vectors are available on Addgene.   
 
Statistics 
Unpaired T-tests were used for Gaussian distributions and Mann-Whitney tests for non-Gaussian 
distributions or for samples of unequal variance. Exact p-values were calculated as reported by 
Prism 6. 
 
Data deposition 
Sequencing data used in this study are in the process of being deposited to public databases and, 
in the meantime, are available upon request.  
 
 
McNeal et al 2020 Methods 
 
RNA sequencing from FFPE tissue and analysis 
 
We previously established a cohort of melanoma specimens presenting with an intact adjacent 
benign nevus (Shain et al., 2018). All cases had been retrieved from the UCSF 
Dermatopathology archive as formalin-fixed paraffin-embedded (FFPE) tissue blocks. 
Histopathologically distinct areas were independently evaluated by a panel of 5-8 
dermatopathologists for staging and genotyped (Shain et al., 2018). Distinct tumor areas were 
manually micro-dissected with a scalpel under a dissection scope from unstained tissue 
sections following the guidance of a pathologist in order to limit stromal cell contamination. 
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Target exon sequencing, phylogenetic analysis, and RNA and small RNA sequencing of each 
tumor area were previously described (Torres et al., 2020) (Shain et al., 2018) 
(phs001550.v2.p1). For this study, fifteen different areas (8 malignant and 7 benign) from seven 
cases were selected based upon BRAF status and confidence of diagnosis. After adaptor 
sequences were removed, small RNA-seq reads were aligned to a human reference (hg37) 
with Bowtie (Langmead et al., 2009)  and then small RNA reference groups (miRBase21) were 
counted.  Differential expression analysis was performed from feature counts using DESeq2 
(Love et al., 2014) with p-values adjusted for multiple testing with the Benjamini-Hochberg 
method (p-adj). Previously published messenger RNA sequencing datasets from Shain et al. 
2018 (Shain et al., 2018) produced from these samples were re-analyzed here with DESeq2.   
 
RNA sequencing from cultured normal and human nevus melanocytes 
 
MicroRNA sequencing libraries were constructed with the TailorMix Small RNA Library 
Preparation Kit (SeqMatic, CA) from total RNA extracted from human melanocytes using TRIzol 
Reagent (Thermo Fisher Cat. # 15596-026) and purified of melanin with the RNeasy Power 
Clean Pro Cleanup Kit (Qiagen Cat. # 13997-50). Sequencing was performed on the Illumina 
HiSeq2500 platform at single-end 50bp. Processing, alignment, and analysis of the reads were 
conducted as described above.  
For mRNA sequencing of melanocytes containing microRNA mimics, synthesized mature 
miRNAs (name and catalog number) were nucleofected into human melanocytes as described 
below. Four days post-nucleofection, total RNA was collected from biological quadruplicates 
with TRIzol Reagent (Thermo Fisher Cat. # 15596-026).  150bp paired end sequencing was 
then conducted on mRNA by GeneWiz. After adaptor sequences were removed, reads were 
aligned to a human reference (hg37) with Bowtie2 and HTSeq was used to count reads.  
Differential expression analysis was performed from normalized counts using EdgeR and 
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LimmaVoom (Law et al., 2014) with p-values adjusted for multiple testing by the Benjamini-
Hochberg method (p-adj). 
 
Cell Derivation and Culture 
 
Benign human melanocytic nevi were excised with informed consent from patient donors at the 
University of California San Francisco Dermatology clinic (San Francisco, CA) according to an 
Institutional Review Board- approved protocol. Patient studies were conducted in accordance 
with the Declaration of Helsinki.  The tissue samples were microdissected to isolate nevus from 
surrounding normal tissue.  Nevus tissue was then mechanically separated into pieces and 
enzymatically dissociated in a 1:1:1 mixture of DMEM:Dispase:Collagenase (DMEM Thermo 
Fisher Cat # 10569044 : Dispase : Collagenase )for 1 hour at 37ºC.  Melanocytes were further 
isolated from epidermal keratinocytes and fibroblasts by selective trypsinization and 5- day 
exposure to 10µg/mL G418 (Geneticin). BRAF status of nevus-derived melanocytes was 
confirmed via sanger sequencing (Quintarabio) using the primer (BRAF forward: 5’- GCA CGA 
CAG ACT GCA CAG GG -3’; BRAF reverse: 5’- AGC GGG CCA GCA GCT CAA TAG -3’). 
BRAFWT (normal) human melanocytes were isolated from de-identified and IRB consented 
neonatal foreskins.  Foreskin tissue was incubated overnight at 4ºC in Dispase and epithelia 
were mechanically separated from the dermis the following morning using forceps.  The 
epithelial tissue was minced and incubated in trypsin for 10min at 37ºC.   Trypsin was quenched 
with DMEM + 10% FBS + 1% antibiotic/antimycotic and tissue was centrifuged at 300xg for 
5min at room temperature.  The supernatant was aspirated and the cell/tissue pellet was 
resuspended in Melanocyte medium (ThermoFisher, M254500) supplemented with HMGS 
(ThermoFisher, S0025) and plated in low volume to promote cell adherence. 
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The 501Mel human melanoma line (Gift from Dr. Boris Bastian, CVCL_4633) were cultured in 
RPMI media with 10% Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin (Pen-Strep), 1% 
L-Glutamine (L-Glut), and 1% Non-Essential Amino Acid (NEAA) cell culture supplement.  
The human melanoma cell line HCIMel019 was derived from patient-derived xenograft (PDX) 
tumors propagated in mice. An HCIMel019 (P2) subcutaneous tumor was resected from a 
mouse and minced in tissue digestion buffer consisting of 100μM HEPES (Gibco, 15630-080), 
5% FBS (DENVILLE, FB5001-H), 20μg/ml gentamicin (Gibco, 15710-064), 1x insulin (Gibco, 
51500-056), and 1mg/ml collagenase IV (Gibco, 17104-019) in DMEM (Gibco, 11965-092). The 
tumor slurry was digested overnight in 37˚C with gently shaking.  The cells were filtered through 
a 100uM pore size filter (Falcon, 352360) and red blood cells were removed with RBC lysis 
buffer consisting of 0.5M EDTA, 0.5M KHCO3 (Sigma, 237205), and 5M NH4CL (Sigma, 
A9434). The remaining cells washed with PBS and cultured in a humidified incubator at 37C 
and 5% CO2 in Mel2 media consisting of 80%MCDB153 (Sigma, M7403), 20% L15 (Gibco, 
11415-064), 2% (DENVILLE, FB5001-H), 1.68mM CaCL (Sigma, C4901), 1x insulin (Gibco, 
51500-056) 5ng/mlEGF 5ng/ml (Sigma Aldrich, E9644), 15μg/ml Bovine Pituitary Extract (Gibco 
13028-014), and 1x Pen/strep (Gibco, 15070-063). 
. 
Mimic Nucleofection 
 
Human melanocytes were trypsinized, quenched with DMEM + 10% FBS + 1% 
antibiotic/antimyotic and centrifuged at 300xg.  The resulting cell pellet was resuspended in R 
Buffer at a concentration of 10,000 cells/µL and 10µL nucleofected with mature miRIDIAN 
microRNA mimics (Dharmacon) (hsa-MIR211-5p C-300566-03-0005, hsa-MIR328-3p C-
300695-03-0005, MIRControl 1 CN-001000-01-05, MIRControl 2 CN-002000-01-05) with a final 
concentration of 4µM.  microRNA LNA inhibitors (Qiagen) (anti-hsa-MIR211-5p YI04103166-
ADC, anti-hsa-MIR328-3p YI04101608-ADC, anti-MIRControl 1 YI00199006-ADC, anti-
MIRControl 2 YI00199007-ADC) were also nucleofected with a final concentration of 4µM 
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nucelofected using the NEON Transfection System and protocol (Thermo Fisher Cat. # 
MPK5000).     
 
Generation of Lentiviral vectors 
 
pTRIPZ-diBRAFV600E was previously described (a gift from Todd Ridky) (McNeal et al. 2015).  
pLVX-AURKB and pLVX-GPR3 were generated by subcloning the respective human cDNA 
(from Addgene # 100142 and #66350) into the [MluI and BamHI sites] of the pLVX-Che-hi3 
vector (a gift Sanford Simon) (Takacs et al. 2017).  pLVX-anti-MIR211-5p, pLVX-anti-MIR328-
3p, and pLVX-Che-zsGreen were generated by inserting zsGreen with or without a 3’UTR into 
the [MluI and XbaI sites] of the pLVX-Che-hi3 vector. The 3’UTRs contained 7 tandem 
microRNA binding sites to both report and inhibit microRNA function, as previously 
described(Judson et al. 2013). ZsGreen was subcloned from pHIV-zsGreen (a gift from Bryan 
Welm & Zena Werb (Addgene plasmid # 18121) (Bledau et al. 2007).  
 
Lentiviral transduction 
 
2.75x106 HEK293T cells were plated in 10cm tissue culture treated dishes and grown for 
approximately 24 hours in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic.  
For each 10cm plate, 3.3µg of pMLV-GagPol and 1.7ug of pVSV-G packaging plasmids were 
added to 500µL of jetPRIME buffer (Polyplus catalog # 712-60) and briefly vortexed to mix 
(Takacs et al 2017).  5µg of lentiviral vector and 20µL of jetPRIME transfection reagent were 
then added to the jetPRIME buffer and the mixture was briefly vortexed.  The mixture was then 
incubated for 10min at room temperature and added to the HEK293T culture media.  48 hours 
post-transfection, viral supernatant was collected and filtered using 0.45µm syringe filters 
(Argos).  Human melanocytes seeded at 1.0x105 – 2.0x105 cells/well density in 6-well plates 
were then incubated in viral supernatant in the presence of 10µg/mL polybrene and centrifuged 
at 300xg for 60 min at room temperature.  Transduced melanocytes were incubated for 15min at 
37ºC after which the viral supernatant was removed and replaced with growth media. 
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Transduced cells were then either selected with puromycin (company, 1µg/mL for 5 days) or 
sorted for mCherry expression using a BD FACSAria II. In some experiments, cells expressing 
pTRIPZ-diBRAFV600E were treated with doxycycline (company, number) at indicated 
concentrations.  
 
Live Quantitative Phase Imaging 
 
Digital holographic cytometry was performed using HoloMonitor M4 imaging cytometers (Phase 
Holographic Imaging, Lund, Sweden) and analyzed for cell proliferation, volume and death 
using HStudio (v2.6.3) as previously described in Hejna et al. 2017 (Hejna et al., 2017). For 
normal human melanocyte proliferation experiments, cells were seeded into 6-well culture 
plates (Sarstedt, 83.3920) at 100,000 cells per well and either live-imaged in a standard 
mammalian cell incubator or serially imaged at different days as indicated. For dose response 
curves, 60,000 501Mel cells or 150,000 HCIMel019 cells were plated per well. The next day, 
media was replaced with media containing indicated concentrations of barasertib (AurK-B 
inhibitor; AZD1152-HQPA | AZD2811) obtained from Selleckchem.com (Catalog No. A1147 – 5 
mg) and cells were imaged for 48-72 hours. Live quantitative phase imaging coupled with 
fluorescent imaging was conducted using the Livecyte platform (Phasefocus, Sheffield, UK).      
 
EdU assays 
 
Normal human melanocytes were nucleofected with microRNA mimics, LNA microRNA 
inhibitors, or infected with lentiviral vectors (as above) and seeded in 48-well plates at a density 
of 50,000 cells/well. 4 days post-seeding EdU was added to culture media at a final 
concentration of 10µM.  24 hours after the addition of EdU, EdU media was removed and cells 
were stained for EdU incorporation and nuclei using the Click-iT EdU Imaging Kit (Thermo 
Fisher Cat. # C10337) and protocol.  Images of EdU and nuclei staining were taking using the 
Evos FL microscope and quantified using FIJI.    
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microRNA qRT-PCR 
 
Total RNA was extracted from melanocytes using TRIzol Reagent (Thermo Fisher Cat. # 
15596-026) and purified of melanin with the RNeasy Power Clean Pro Cleanup Kit (Qiagen Cat. 
# 13997-50).  RNA concentrations were established by NanoDrop.  microRNAs were then 
converted to cDNA using TaqMan Advanced miRNA Assays (Thermo Fisher Cat. # A25576).  
Quantitative PCR was carried out in triplicate using the TaqMan Fast Advanced Master Mix 
(Thermo Fisher Cat. # 4444557) and TaqMan probes corresponding to each microRNA of 
interest on an Applied Biosystems 7900HT machine.  MIR191-5p and MIR26a-5p were used as 
reference controls and the delta-delta CT method was used to approximate gene expression.  
 
Western Blotting 
 
Protein was collected using RIPA Buffer (Thermo Fisher Cat. # 89901) supplemented with 
HALT Protease Inhibitor (Thermo Fisher Cat. # 87786).  Protein extracts were mixed with 
NuPAGE LDS Sample Buffer (ThermoFisher Cat. # NP0007), NuPAGE Sample Reducing 
Agent (ThermoFisher Cat. # NP0004) and heated for 10 min at 90 °C. Protein was resolved on 
NuPAGE Novex 4–12% Bis-Tris Protein Gels, 1.0 mm, 15-well (ThermoFisher Cat. # 
NP0323BOX) and transferred using a Mini-Trans-Blot Cell onto 0.22µm PVDF membranes 
(ThermoFisher Cat. # 88520). Membranes were blocked with Membrane Blocking Solution 
(ThermoFisher Cat. # 000105) for 20 min. at room temperature (22 °C). The membranes were 
then incubated overnight at 4 °C with primary antibodies at the following dilutions: anti-HSP90 
(CST Cat. # 4874) 1:1000, anti-BRAFV600E (Spring Bioscience Corp Cat. # E19292) 1:1000, 
anti-phosphoERK1/2 (CST Cat. # 4970) 1:1000, anti-AURKB (Abcam ab2254) 1:1000. The 
membranes were then washed four times with PBS and 0.5% Tween20 (TBST) and incubated 
with horseradish peroxidase-conjugated secondary antibody 1:2000 for 30 min. at room 
temperature. The membranes were then washed four times with TBST and were visualized with 
Lumina Forte Western HRP substrate (Millipore Cat. # WBLUF0500). 
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Cell cycle and apoptosis profiling 
Melanocytes were trypsinized with 0.05% Trypsin (Thermo Fisher Cat# 25300120) and 
quenched with DMEM + 10% FBS + 1% antibiotic/antimycotic.  Cells were centrifuged at 1000 
rpm for 5 min. The supernatant was aspirated, and cells were resuspended in ice cold 1X PBS 
with 3% BSA. Cells were centrifuged for additional 1 min and cells were resuspended in 500µL 
of ice cold 70% ethanol.  Cells were then fixed for 1 hr at 4ºC.  After fixation, cells were 
centrifuged for 5 min at 1000rpm and washed 1X PBS with 3% BSA.  Cells were resuspended 
in 200µL of 1X PBS with 0.5mg/mL propidium iodide (PI) (BioLegend Cat# 421301) and 
incubated in the dark at room temperature for 30 min.  PI stained cells were analyzed with BD 
FACs Verse.  
 
Annexin V/PI staining was performed by trpysinizing melanocytes as above.  Cells were washed 
with PBS and resuspended with Annexin V binding buffer  (BioLegend Cat# 422201) at a 
concentration of 1X10^6 cell/mL.  5µL of APC Annexin V antibody (BioLegend Cat# 640919) 
and 10µL of PI were added.  Cells were gently vortexed and incubated 15min at room 
temperature in the dark.  400µL of Annexin V Binding Buffer was added and samples were 
analyzed on the BD FACs Verse. 
 
Human nevus and melanoma tissue Immunohistochemistry 
 
The clinical samples used in the study were procured with IRB approval from the archives of the 
UCSF Dermatopathology and Oral Pathology Service. All samples, 11 melanoma and 11 
melanocytic nevi, had received prior pathological diagnosis by board-certified 
dermatopathologists (THM and UEL), were de-identified and re-verified histologically (UEL). 
Tissue was fixed in 10% neutral-buffered formalin, routinely processed, embedded in paraffin, 
and stained with hematoxylin and eosin. Formalin-fixed paraffin-embedded sections of 4 μm 
thickness were stained with antibodies specific for AURKB (1:400 dilution, Abcam ab2254) and 
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GPR3 (1:125 dilution, Abnova H00002827-M01). Review of immunohistochemical stains was 
performed by UEL with semiquantitative grading for GPR3 (0=none; 1=patchy positive; 2=strong 
positive) and AURKB (0=none; 1=rare positive; 2=scattered positive; 3= frequent positive; 
4=many positive). 
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